<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        15-244-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEPAKINE CHRONO 500MG TABS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALPROATE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        61
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi-aventis" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Depakine Chrono is</strong></p><p>The name of your medicine is Depakine Chrono 500mg Controlled Release Tablets (called Depakine Chrono in this leaflet). &ldquo;Controlled release&rdquo; means that the active ingredient sodium valproate is slowly released from the tablets over a period of time.</p><p><strong>What Depakine Chrono contains</strong></p><p>Depakine Chrono contains sodium valproate. It belongs to a group of medicines called anti-convulsants or anti-epileptic agents. It works by helping to calm the brain down.</p><p><strong>What Depakine Chrono is used for</strong></p><p>Depakine Chrono is used to treat epilepsy (fits) in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Depakine Chrono and tell your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic (hypersensitive) to sodium valproate or any of the other ingredients of Depakine Chrono (see Section 6: Contents of the pack and other information).<br />Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems or you or your family have a history of liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a rare illness called porphyria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a known metabolic disorder, i.e. a urea cycle disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a genetic problem caused by a mitochondrial disorder (e.g Alpers-Huttenlocher syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant, unless nothing else works for you (see &lsquo;Pregnancy, breast-feeding and fertility &ndash; Important advice for women&rsquo; below).</p><p>If you are a woman able to have a baby you must not take Depakine Chrono unless you use an effective method of birth control (contraception) at all times during your treatment with Depakine Chrono. Do not stop taking Depakine Chrono or your contraception until you have discussed this with your doctor. Your doctor will advise you further (see below under &lsquo;Pregnancy, breast-feeding and fertility &ndash; Important advice for women&rsquo;).</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Depakine Chrono.</p><p><strong>Warnings and precautions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A small number of people being treated with anti-epileptics such as sodium valproate have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As with other anti-epileptic drugs, convulsions may become worse or happen more frequently whilst taking this medicine. If this happens contact your doctor immediately.</p><p><strong>Talk to your doctor or pharmacist before taking Depakine Chrono if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes. This medicine may affect the results of urine tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a carnitine palmitoyltransferase type II deficiency.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems. Your doctor may give you a lower dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have fits (epilepsy), brain disease or a metabolic condition affecting your brain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a &lsquo;urea cycle disorder&rsquo; where too much ammonia builds up in the body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an illness called &lsquo;systemic lupus erythematosus (SLE)&rsquo; &ndash; a disease of the immune system which affects skin, bones, joints and internal organs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know that there is a genetic problem caused by a mitochondrial disorder in your family.</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Depakine Chrono.</p><p><strong>Weight gain</strong></p><p>Taking Depakine Chrono may make you put on weight. Talk to your doctor about how this will affect you.</p><p><strong>Blood tests</strong></p><p>Your doctor may wish to do blood tests before you start taking Depakine Chrono and during your treatment.</p><p><strong>Other medicines and Depakine Chrono</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you buy without a prescription, including herbal medicines. This is because Depakine Chrono can affect the way some other medicines work. Also some medicines can affect the way Depakine Chrono works.</p><p><strong>The following medicines can increase the chance of you getting side effects, when taken with Depakine Chrono:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used for pain and inflammation (salicylates) such as aspirin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some other medicines used to treat fits (epilepsy) &ndash; see page 2, section 3, &lsquo;Patients taking other medicines for fits&rsquo;. This includes medicines such as phenobarbital, primidone, phenytoin, carbamazepine, rufinamide, topiramate, acetazolamide, lamotrigine and felbamate.</p><p><strong>Depakine Chrono may increase the effect of the following medicines:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used for thinning the blood (such as warfarin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zidovudine used to treat HIV infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temozolomide used to treat cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monoamine oxidase inhibitors (MAOI) such as moclobemide, selegiline, linezolid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to calm emotional and mental health problems (including schizophrenia, bipolar disorder and depression) such as quetiapine, diazepam and olanzapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nimodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol &ndash; used for anaesthesia.</p><p><strong>The following medicines can affect the way Depakine Chrono works:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used for the prevention and treatment of malaria such as mefloquine and chloroquine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine used for stomach ulcers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors such as lopinavir and ritonavir &ndash; used for HIV infection and AIDS.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbapenem agents (antibiotics used to treat bacterial infections) such as imipenem, meropenem, rifampicin and erythromycin. The combination of Depakine Chrono and carbapenems should be avoided because it may decrease the effect of your medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholestyramine used to lower blood fat (cholesterol) levels.</p><p><strong>Taking Depakine Chrono with food and drink</strong></p><p>Alcohol intake is not recommended during treatment.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>Important advice for women</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not use Depakine Chrono if you are pregnant, unless nothing else works for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a woman able to have a baby, you must not take Depakine Chrono unless you use an effective method of birth control (contraception) during your entire treatment with Depakine Chrono.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Depakine Chrono or your birth control (contraception), until you have discussed this with your doctor. Your doctor will advise you further.</p><p><strong>The risks of valproate when taken during pregnancy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor immediately if you are planning to have a baby or are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valproate carries a risk if taken during pregnancy. The higher the dose, the higher the risks but all doses carry a risk.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It can cause serious birth defects and can affect the way in which the child develops as it grows. Birth defects which have been reported include <em>spina bifida</em> (where the bones of the spine are not properly developed); facial and skull malformations; heart, kidney, urinary tract and sexual organ malformations; limb defects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take valproate during pregnancy you have a higher risk than other women of having a child with birth defects that require medical treatment. Because valproate has been used for many years we know that in women who take valproate around 10 babies in every 100 will have birth defects. This compares to 2-3 babies in every 100 born to women who don&rsquo;t have epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is estimated that up to 30-40% of preschool children whose mothers took valproate during pregnancy may have problems with early childhood development. Children affected can be slow to walk and talk, intellectually less able than other children, and have difficulty with language and memory.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Autistic spectrum disorders are more often diagnosed in children exposed to valproate and there is some evidence children may be more likely to develop symptoms of Attention Deficit Hyperactivity Disorder (ADHD).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before prescribing this medicine to you, your doctor will have explained what might happen to your baby if you become pregnant whilst taking valproate. If you decide later you want to have a child you should not stop taking your medicine or your method of birth control (contraception) until you have discussed this with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a parent or a caregiver of a female child treated with valproate, you should contact their doctor once your child experiences their first period (menarche).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ask your doctor about taking folic acid when trying for a baby. Folic acid can lower the general risk of <em>spina bifida</em> and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.</p><p><strong>Please choose the situations which apply to you and read the descriptions below:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>I AM STARTING TREATMENT WITH Depakine CHRONO</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>I AM TAKING Depakine CHRONO AND NOT PLANNING TO HAVE A BABY</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>I AM TAKING Depakine CHRONO AND PLANNING TO HAVE A BABY</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>I AM PREGNANT AND I AM TAKING Depakine CHRONO</strong></p><p><strong>I AM STARTING TREATMENT WITH Depakine CHRONO</strong></p><p>If this is the first time you have been prescribed Depakine Chrono your doctor will have explained the risks to an unborn child if you become pregnant. Once you are able to have a baby, you will need to make sure you use an effective method of birth control (contraception) without interruption throughout your treatment with Depakine Chrono. Talk to your doctor or family planning clinic if you need advice on birth control (contraception).</p><p><strong>Key messages:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy must be excluded before start of treatment with Depakine Chrono with the result of a pregnancy test, confirmed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use an effective method of birth control (contraception) during your entire treatment with Depakine Chrono.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must discuss appropriate methods of birth control (contraception) with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist for advice on birth control (contraception).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must get regular (at least annual) appointments with a specialist experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware of and have understood all the risks and advice related to the use of valproate during pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you want to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor <strong>immediately</strong> if you are pregnant or think you might be pregnant.</p><p><strong>I AM TAKING Depakine CHRONO AND NOT PLANNING TO HAVE A BABY</strong></p><p>If you are continuing treatment with Depakine Chrono but you are not planning to have a baby make sure you are using an effective method of birth control (contraception) without interruption during your entire treatment with Depakine Chrono. Talk to your doctor or family planning clinic if you need advice on birth control (contraception).</p><p><strong>Key messages:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use an effective method of birth control (contraception) during your entire treatment with Depakine Chrono.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must discuss birth control (contraception) with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist for advice on birth control (contraception).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must get regular (at least annual) appointments with a specialist experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware of and have understood all the risks and advice related to the use of valproate during pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you want to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor <strong>immediately</strong> if you are pregnant or think you might be pregnant.</p><p><strong>I AM TAKING Depakine CHRONO AND PLANNING TO HAVE A BABY</strong></p><p>If you are planning to have a baby, first schedule an appointment with your doctor.</p><p>Do not stop taking Depakine Chrono or your birth control (contraception) until you have discussed this with your doctor. Your doctor will advise you further.</p><p>Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with development, which can be seriously debilitating. Your doctor will refer you to a specialist experienced in the management of epilepsy, so that alternative treatment options can be evaluated early on. Your specialist can put several actions in place so that your pregnancy goes as smoothly as possible and any risks to you and your unborn child are reduced as much as possible.</p><p>Your specialist may decide to change the dose of Depakine Chrono, switch you to another medicine, or stop treatment with Depakine Chrono a long time before you become pregnant &ndash; this is to make sure your illness is stable.</p><p>Ask your doctor about taking folic acid when trying for a baby. Folic acid can lower the general risk of <em>spina bifida</em> and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.</p><p><strong>Key messages:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Depakine Chrono unless your doctor tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop using your birth control (contraception) before you have talked to your doctor and worked together on a plan to ensure your condition is controlled and the risks to your baby are reduced.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First schedule an appointment with your doctor. During this visit your doctor will make sure you are well aware of and have understood all the risks and advice related to the use of valproate during pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will try to switch you to another medicine or stop treatment with Depakine Chrono a long time before you become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schedule an urgent appointment with your doctor if you are pregnant or think you might be pregnant.</p><p><strong>I AM PREGNANT AND I AM USING Depakine CHRONO</strong></p><p>Do not stop taking Depakine Chrono unless your doctor tells you to as your condition may become worse.</p><p>Schedule an urgent appointment with your doctor if you are pregnant or think you might be pregnant. Your doctor will advise you further.</p><p>Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with development which can be seriously debilitating. You will be referred to a specialist experienced in the management of epilepsy so that alternative treatment options can be evaluated.</p><p>In the exceptional circumstances when Depakine Chrono is the only available treatment option during pregnancy, you will be monitored very closely both for the management of your underlying condition and to check how your unborn child is developing. You and your partner should receive counselling and support regarding the valproate exposed pregnancy.</p><p>Ask your doctor about taking folic acid. Folic acid can lower the general risk of <em>spina bifida</em> and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.</p><p><strong>Key messages:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schedule an urgent appointment with your doctor if you are pregnant or think you might be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Depakine Chrono unless your doctor tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you are referred to a specialist experienced in the treatment of epilepsy to evaluate the need for alternative treatment options.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must get thorough counselling on the risks of Depakine Chrono during pregnancy, including malformations and developmental effects in children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you are referred to a specialist for prenatal monitoring in order to detect possible occurrences of malformations.</p><p><strong>Make sure you read the Patient Guide that you will receive from your doctor. Your doctor will discuss the Annual Risk Acknowledgement Form and will ask you to sign it and keep it. You will also receive a Patient Card from your pharmacist to remind you of valproate risks in pregnancy.</strong></p><p><strong>Newborn babies of mothers who took valproate during pregnancy may have:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clotting problems (such as blood not clotting very well). This may appear as bruising or bleeding which takes a long time to stop.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypoglycaemia (low blood sugar).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypothyroidism (underactive thyroid gland, which can cause tiredness or weight gain).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdrawal syndrome (including agitation, irritability, hyperexcitability, jitteriness, hyperkinesia, muscle problems, tremor, convulsions and feeding problems). In particular, this may occur in newborns whose mothers have taken valproate during the last trimester of their pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Very little Depakine Chrono gets into the breast milk. However, talk to your doctor about whether you should breast-feed your baby.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>You may feel sleepy when taking Depakine Chrono. If this happens to you, do not drive or use any tools or machines. Taking other medicines used to treat fits or calm emotional and mental health problems may increase sleepiness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Depakine Chrono exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Depakine Chrono treatment must be started and supervised by a doctor specialised in the treatment of epilepsy.</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how much Depakine Chrono to give you or your child depending on your or your child&rsquo;s body weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Depakine Chrono with or after food. This will help to stop the feelings of sickness that may happen after taking Depakine Chrono.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> crush or chew the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you feel the effect of your medicine is too weak or too strong, do not change the dose yourself but ask your doctor.</p><p><strong>How to take this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine can be taken once or twice daily.</p><p><strong>How much to take</strong></p><p><strong>Adults (including the elderly)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is 600mg daily. Your doctor will gradually increase this dose by 200mg every 3 days depending on your condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is generally between 1000mg and 2000mg (20-30mg per kilogram of body weight) each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This may be increased to 2500mg each day depending on your illness.</p><p><strong>Children over 20 kilograms</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose should be 400mg daily. Your doctor should increase this dose depending on your child&rsquo;s illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is then between 20mg and 30mg for each kilogram of body weight each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This may be further increased to 35mg for each kilogram of body weight each day depending on your child&rsquo;s illness.</p><p><strong>Children under 20 kilograms</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depakine Chrono is not recommended in children that weigh less than 20 kilograms. Depakine Liquid (sugar free) or Depakine Syrup is recommended instead.</p><p><strong>Patients with kidney problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may decide to adjust your or your child&rsquo;s dose.</p><p><strong>Patients taking other medicines for fits (epilepsy)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your child may be taking other medicines for epilepsy at the same time as Depakine Chrono. If so, your doctor should gradually initiate treatment depending on your or your child&rsquo;s condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase the dose of Depakine Chrono by 5-10mg for each kilogram of body weight each day depending on which other medicines you are taking.</p><p><strong>If you take more Depakine Chrono than you should</strong></p><p>If you take more Depakine Chrono than you should, tell a doctor or go to a hospital casualty department straight away. Take the medicine pack with you. This is so the doctor knows what you have taken.</p><p>The following effects may happen: feeling sick or being sick, pupils of the eye become smaller, dizziness, loss of consciousness, weak muscles and poor reflexes, breathing problems, headaches, fits (seizures), confusion, memory loss and unusual or inappropriate behaviour.</p><p><strong>If you forget to take Depakine Chrono</strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose. <strong>Do not</strong> take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Depakine Chrono</strong></p><p>Keep taking until your doctor tells you to stop. Do not stop taking Depakine Chrono just because you feel better. If you stop your fits may come back.</p><p><strong>Tests</strong></p><p>Make sure you or your child keep your regular appointments for a check-up. They are very important as your or your child&rsquo;s dose may need to be changed. Depakine Chrono can change the levels of liver enzymes shown up in blood tests. This can mean that your or your child&rsquo;s liver is not working properly. If you or your child go into hospital or visit another doctor or a dentist, tell them you are taking Depakine Chrono.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Depakine Chrono can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an <strong>allergic reaction</strong>. The signs include: a rash, joint pain, fever (systemic lupus erythematosus), swallowing or breathing problems, swelling of your lips, face, throat or tongue. Hands, feet or genitals may also be affected. More severe allergic reactions can lead to lymph node enlargement and possible impairment of other organs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver problems and problems of the pancreas may show as a sudden illness which may happen in the first six months of treatment. This happens in a very small number of people taking Depakine Chrono. It includes feeling and being sick many times; being very tired, sleepy and weak; stomach pain including very bad upper stomach pain; jaundice (yellowing of the skin or whites of the eyes); loss of appetite; swelling (especially of the legs and feet but may include other parts of the body); worsening of your fits or a general feeling of being unwell. Your doctor may tell you to stop taking Depakine Chrono immediately if you have these symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a skin rash or skin lesions with a pink/red ring and a pale centre which may be itchy, scaly or filled with fluid. The rash may appear especially on the palms or soles of your feet. These could be signs of a serious allergy to the medicine called &lsquo;erythema multiforme&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blistering or bleeding of the skin around the lips, eyes, mouth, nose and genitals. Also flu-like symptoms and fever. This may be something called &lsquo;Stevens-Johnson syndrome&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe blistering rash where layers of the skin may peel off to leave large areas of raw exposed skin over the body. Also a feeling of being generally unwell, fever, chills, and aching muscles. This may be something called &lsquo;Toxic epidermal necrolysis&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising more easily and getting more infections than usual. This could be a blood problem called &lsquo;thrombocytopenia&rsquo;. It can also be due to a fall in the number of white blood cells, bone marrow depression or another condition that affects red blood cells, white blood cells and platelets (pancytopenia) or how the blood clots.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clotting problems (bleeding for longer than normal), bruising or bleeding for no reason.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in mood, loss of memory, lack of concentration and deep loss of consciousness (coma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Underactive thyroid gland, which may cause tiredness or weight gain (hypothyroidism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulty and pain due to inflammation of the lungs (pleural effusion).</p><p><strong>Tell your doctor as soon as possible if you have any of the following side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour including being very alert, and sometimes also aggressive, hyperactive and unusual or inappropriate behaviour. This is more likely if other medicine to treat fits such as phenobarbital and topiramate are taken at the same time or if the Depakine Chrono starting dose is high or has been suddenly increased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the amount of ammonia in the blood. Symptoms of this condition are being sick, problems with balance and co-ordination, feeling lethargic or less alert.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling shaky (tremor), sleepy or unsteady when walking or jerky muscle movements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired or confused with loss of consciousness sometimes accompanied by hallucinations or fits.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blisters with the skin flaking away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid, uncontrollable movement of the eyes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the number and severity of convulsions.</p><p><strong>Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea), being sick (vomiting), stomach ache or diarrhoea, especially when starting treatment. This may be helped by taking the tablets with food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of gums or sore mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nail and nail bed disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin problems such as rashes. These happen rarely, but more often in people also taking lamotrigine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss which is usually temporary. When it grows back it may be more curly than before.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair disorders (changes in texture, colour or growth)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased levels of some hormones (androgens), which may lead to increased hair growth on the face, breasts or chest, acne or thinning hair.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash caused by narrow or blocked blood vessels (vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in women&rsquo;s periods and increased hair growth in women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in men</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the feet and legs (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain &ndash; as your appetite may be increased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems, bedwetting or increased need to pass urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seeing or hearing things that are not there (hallucinations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression, agitation, disturbance in attention, abnormal behaviour, restlessness/hyperactivity, and learning disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness in the hands and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lowering of normal body temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal blood clotting factors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain and weakness (rhabdomyolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Obesity</p><p><strong>Bone disorders</strong></p><p>There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term anti-epileptic medication, have a history of osteoporosis, or take steroids.</p><p><strong>Blood tests</strong></p><p>Depakine Chrono can change levels of liver enzymes, salts or sugars shown up on blood and urine tests.</p><p><strong>Male fertility</strong></p><p>Taking Depakine Chrono can be a contributing factor in male infertility.</p><p><strong>&nbsp;</strong><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sanofi- Pharmacovigilance:<strong> </strong>KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN</p><p>&nbsp;</p><p>Do not use <strong>Depakine Chrono </strong>after the expiry date which is stated on the box.</p><p>&nbsp;</p><p>Store below 30&deg;C and protected from moisture.</p><p>The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>W</strong><strong>h</strong><strong>at Depakine Chrono 500 mg prolonged-release scored film-coated tablets contain</strong></p><p>&bull;&nbsp;&nbsp; &nbsp;The active substance is:</p><p>&nbsp;</p><p>Sodium valproate ..................................................................................................... 333.00 mg</p><p>Valproic acid ............................................................................................................ 145.00 mg</p><p>Amount equivalent to sodium valproate ................................................................ 500.00 mg</p><p>For one scored film-coated tablet.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&nbsp;</p><p>Ethylcellulose 20 mPa.s, hypromellose 3000 mPa.s, anhydrous colloidal silica, hydrated colloidal silica, sodium saccharin, hypromellose 6 mPa.s, macrogol 6000, polyacrylate dispersion 30% (EUDRAGIT&reg; E30D), talc, titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Depakine Chrono looks like and contents of the pack
This medicine is supplied as scored film-coated tablets. Boxes of 30, 40, 60 or 100 tablets.

Not all pack size may be marketed in your country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>sanofi-aventis France</p><p>82, avenue Raspail</p><p>94250 Gentilly &ndash; France</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Sanofi Winthrop Industrie</p><p>1, rue de la Vierge - Ambares et Lagrave, 33565 Carbon Blanc Cedex France, AMBARES, 33565, France</p><p><strong>&nbsp;</strong></p><p><strong>Seconday packaging</strong></p><p>Sanofi Aventis Arabia Co. Ltd, Industrial Valley Phase 1A St. KAEC,, King Abdullah Economic City, KAEC - Rabigh, 21423, Saudi Arabia.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو ديباكين كرونو</strong><br />اسم الدواء الخاص بك هو ديباكين كرونو 500 مجم، أقراص مديدة التحرّر قاومة للمعدة (يُسمى ديباكين كرونو في هذه النشرة). &quot;مضبوطة التحرّر&quot; يعني أن العنصر النشط من الصوديوم فالبروات يتم تحريره من القرص ببطء خلال فترة زمنية.<br /><strong>ماذا يحتوي ديباكين كرونو</strong><br />يحتوي ديباكين كرونو على صوديوم فالبروات. وهو ينتمي إلى مجموعة من الأدوية تُسمى مضادات الصرع. تعمل هذه الأدوية على تهدئة الدماغ.</p><p>&nbsp;</p><p><strong>ما هي دواعي استخدام ديباكين كرونو</strong><br />يُستخدم ديباكين في علاج الصّرَع (النوبات) لدى الأطفال والبالغين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong><u>المحاذير:</u></strong><br /><strong>تجنّب تناول ديباكين كرونووأخبر طبيبك في الحالات التالية:</strong></p><p>- إذا كان لديك حساسية (فرط التحسس) نحو الفالبروات، أو نحو أي من المكونات الأخرى في هذا الدواء.<br />&nbsp;&nbsp; تتضمن علامات الحساسية ما يلي: طفح جلدي، صعوبة في البلع أو التنفس، تورم شفاهك، وجهك،<br />&nbsp;&nbsp; حلقك أو لسانك.</p><p>- إذا كان لديك أمراض في الكبد، أو تاريخ شخصي أو عائلي من الإصابة بأمراض الكبد.</p><p>- إذا كان لديك مرض نادر يُسمّى البورفيريا.</p><p>- إذا كان لديك اضطراب أيضي معروف،&nbsp; أي اضطراب دورة اليوريا.</p><p><em>- </em>إذا كان لديك مرض وراثي ناجم عن اضطراب في الميتوكوندريا (مثل متلازمة ألبيرس-هتنلوشر)</p><p><em>-</em> إذا كنتِ حاملاً، ما لم يكن هناك دواء آخر يناسبك (أنظري &quot;الحمل والرضاعة والخصوبة&quot; -&nbsp; نصائح<br />&nbsp;&nbsp; مهمة للنساء أدناه).</p><p>&nbsp;</p><p>إذا كنتِ امرأة في سنّ الإنجاب، يجب عليك عدم تناول ديباكين كرونو إلا إذا كنت تستخدمين وسيلة فعالة لتحديد النسل (منع الحمل) في جميع الأوقات خلال فترة العلاج بديباكين. لا تتوقفي عن تناول ديباكين كرونو أو عن استخدام وسائل منع الحمل الخاصة بك حتى تناقشي هذا الأمر مع طبيبك. سيقدّم لك طبيبك المزيد من المعلومات (انظري أدناه تحت عنوان &quot;الحمل والرضاعة الطبيعية والخصوبة - نصائح مهمة للنساء&quot;).</p><p>&nbsp;</p><p>لا تتناول هذا الدواء إذا كان أيّ مما سبق ينطبق عليك. إذا لم تكن متأكداً، تحدث إلى طبيبك أو الصيدلي قبل استخدام ديباكين كرونو.</p><p><em>&nbsp;</em></p><p><strong>الاحتياطات والتحذيرات<br />- </strong>لقد لوحظ ورود أفكار تدعو للانتحار أو لإيذاء النفس لدى عدد قليل من المرضى الذين يتناولون&nbsp;<br />&nbsp;&nbsp; مضادات الصرع مثل صوديوم فالبروات. إذا كان لديك أي نوع من هذه الأفكار، اتصل بطبيبك على<br />&nbsp;&nbsp; الفور.<br />- كما هو الحال مع مضادات الصرع الأخرى، قد تحدث زيادة في تواتر النوبات أو قد تتفاقم حدتها<br />&nbsp;&nbsp; أثناءالعلاج بهذا الدواء. إذا حدث هذا، يجب استشارة الطبيب فورا.</p><p>&nbsp;</p><p><strong>استشر طبيبك أو الصيدلي قبل استخدام ديباكين كرونو إذا كان لديك:</strong><br />* &nbsp;مرض السكري. قد يؤثّر هذا الدواء على نتائج فحص البول.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; نقص إنزيم كارنيتين بالميتويل ترانسفيريز من النوع الثاني.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى، قد يصف لك طبيبك جرعة أقل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تشنّجات (صرع)، أو مرض في الدماغ، أو اضطراب أيضي يُؤثّر على الدّماغ لديك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; &quot;اضطراب في دورة اليوريا&quot; الذي يُؤدي إلى تجمّع الأمونيا في الجسم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض يُسمّى &quot;الذئبة الحمامية الجهازية (SLE)&quot; &ndash; مرض يُصيب جهاز المناعة يؤثّر على الجلد،<br />&nbsp;&nbsp; والعظام، والمفاصل، والأعضاء الداخليّة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; علم بوجود مرض وراثي عائلي لديك بسبب اضطراب في الميتوكوندريا.</p><p>&nbsp;</p><p>إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، تحدث إلى طبيبك أو الصيدلي قبل تناول ديباكين كرونو.</p><p>&nbsp;</p><p><strong>زيادة الوزن</strong></p><p>قد يؤدي استخدام ديباكين كرونو إلى زيادة الوزن لديك. تحدث مع طبيبك حول كيفية تأثير ذلك عليك.</p><p>&nbsp;</p><p><strong>تحاليل الدم</strong></p><p>قد يرغب طبيبك في إجراء فحوص الدم لك قبل البدء في تناول ديباكين كرونو وأثناء العلاج .</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وديباكين</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية والأدوية العُشبية. ذلك لأنه يمكن أن يؤثر ديباكين كرونو على طريقة عمل بعض الأدوية الأخرى، كما يُمكن أيضاً أن تُؤثر بعض الأدوية الأخرى على طريقة عمل ديباكين كرونو.</p><p>&nbsp;</p><p><strong>استخدام الأدوية التالية مع ديباكين كرونو قد يزيد من فرصة تعرضك لآثار جانبية:</strong></p><p>&bull; بعض الأدوية المستخدمة للألم والالتهاب (الساليسيلات) مثل الأسبرين.</p><p>&bull; بعض الأدوية الأخرى المستخدمة لعلاج النوبات (الصرع) - انظر الصفحة 2، الفقرة 3، &quot;المرضى<br />&nbsp; الذين يتناولون أدوية أخرى لعلاج النوبات&quot;. وهذا يشمل الأدوية مثل الفينوباربيتال، والبريميدون،<br />&nbsp; والفينيتوين، والكاربامازبين، والرافيناميد، توبيراميت، أسيتازولاميد، لاموتريجين وفلباميت.</p><p>&nbsp;</p><p><strong>قد يزيد ديباكين كرونومن تأثير الأدوية التالية:</strong></p><p>&bull; الأدوية التي تعمل على سيولة الدم (مثل الوارفارين).</p><p>&bull; زيدوفودين - يستخدم لعلاج الإصابة بفيروس نقص المناعة البشرية.</p><p>&bull; تيموزولوميد الذي يُستخدم في علاج السرطان.</p><p>&bull; الأدوية التي تُستخدم لعلاج الاكتئاب.</p><p>&bull; مثبطات إنزيم أوكسيداز أحادي الأمين (MAOI) مثل موكلوبيميد، سيلجيلين، لينزوليد.</p><p>&bull; الأدوية المستخدمة لتهدئة المشاكل النفسية والعاطفية (بما في ذلك الفصام والاضطراب ثنائي القطب<br />&nbsp; والاكتئاب) مثل كيتابيم والديازيبام والأولانزيبين.</p><p>&bull; النيموديبين.</p><p>&bull; البروبوفول - يستخدم للتخدير.</p><p>&nbsp;</p><p><strong>يمكن أن تؤثر الأدوية التالية على طريقة عمل ديباكين كرونو:</strong></p><p>&bull; بعض الأدوية المستخدمة للوقاية والعلاج من الملاريا مثل الميفلوكين والكلوروكوين.</p><p>&bull; السيميتيدين - يستخدم لعلاج قرحة المعدة.</p><p>&bull; مثبطات البروتياز مثل لوبينافير و ريتونافير - تستخدم لعلاج الإصابة بفيروس نقص المناعة البشرية<br />&nbsp; والإيدز.</p><p>&bull; أدوية كاربابينيم (المضادات الحيوية المستخدمة لعلاج الالتهابات البكتيرية) مثل إيميبينيم، وميروبينيم،<br />&nbsp; وريفامبيسين، وإريثروميسين. يجب تجنب الاستخدام المتزامن لديباكين كرونو مع أي دواء من مجموعة<br />&nbsp; كاربابينيم لأنه قد يقلل من تأثير الديباكين كرونو.</p><p>&bull; كوليستيرامين الذي يُستخدم لخفض مستويات الدهون في الدم (الكوليسترول).</p><p>&nbsp;</p><p><strong>تناول ديباكين كرونو مع الطعام والشراب</strong></p><p>لا يُنصح بتناول الكحول أثناء العلاج.</p><p><strong>&nbsp;</strong></p><p><strong>الحمل والرضاعة الطبيعية والخصوبة<br />نصائح مُهمة للنساء </strong><br />&bull;<strong> </strong>يجب أن لا تتناولي هذا الدواء إذا كنت حاملا أو في سن الإنجاب ما لم يرد خلاف ذلك من قبل الطبيب.</p><p>&bull; إذا كنتِ امرأة في سنّ الإنجاب، يجب عليك عدم تناول ديباكين كرونو إلا إذا كنت تستخدمين وسيلة فعالة<br />&nbsp; لتحديد النسل (منع الحمل) في جميع الأوقات خلال فترة العلاج بديباكين كرونو.&nbsp;</p><p>&bull; لا تتوقفي عن تناول ديباكين كرونو أو عن استخدام وسائل منع الحمل الخاصة بك حتى تناقشي هذا<br />&nbsp; الأمر مع طبيبك. سيقدّم لك طبيبك المزيد من المعلومات.</p><p>&nbsp;</p><p><strong>مخاطر استخدام فالبروات أثناء الحمل</strong></p><p>&bull; أخبري طبيبك على الفور إذا كنت تخططين لإنجاب طفل أو إذا كنتِ حاملاً.</p><p>&bull; هناك خطر ينجم عن استخدام فالبروات أثناء الحمل. كلما زادت الجرعة، زادت المخاطر ولكن جميع<br />&nbsp; الجرعات تحمل مخاطر.</p><p>&bull; يمكن أن يسبب ديباكين كرونو تشوهات خِلقية خطيرة ويمكن أن يؤثر على الطريقة التي يتطور بها نمو<br />&nbsp; الطفل في مراحل النمو المختلفة. العيوب الخلقية التي تم الإبلاغ عنها تشمل انشقاق العمود الفقري (حيث<br />&nbsp; تكون عظام العمود الفقري غير متطورة بشكل صحيح)؛ تشوهات الوجه والجمجمة؛ والقلب والكلى والمسالك<br />&nbsp; البولية وتشوهات الجهاز التناسلي؛ وتشوهات في الأطراف.</p><p>&bull; إذا تناولتِ الفالبروات أثناء الحمل، فأنت مُعرّضة لخطر إنجاب طفل يعاني من عيوب خلقية تتطلب<br />&nbsp; علاجًا طبيًا أكثر من النساء الأخريات. ولأن فالبروات استُخدم لسنوات عديدة، فإننا نعلم أن النساء اللواتي<br />&nbsp; يتناولن الفالبروات يُنجبن أطفال يعانون من عيوب خِلقية بما يصل إلى حوالي 10 أطفال في كل 100<br />&nbsp; طفل. وذلك بالمقارنة مع 2-3 أطفال في كل 100 مولود لنساء لا يعانين من الصرع.</p><p>&bull; تشير التقديرات إلى أن ما يصل إلى 30-40٪ من الأطفال ما قبل سنّ المدرسة ممن استخدمت أمهاتهم<br />&nbsp; الفالبروات أثناء الحمل قد يعانون من مشاكل في النمو في الطفولة المبكرة. يمكن أن يظهر لدى الأطفال<br />&nbsp;&nbsp;المتأثرين بطء في المشي والحديث، وتدني في قدرتهم على التفكير مقارنة بالأطفال الآخرين، وصعوبة في<br />&nbsp;&nbsp;التحدّث والذاكرة.</p><p>&bull; غالباً ما يتم تشخيص اضطرابات طيف التوحد لدى الأطفال الذين تعرّضوا للفالبروات أثناء الحمل، وهناك<br />&nbsp; بعض الأدلة على أن هؤلاء الأطفال قد يكونوا أكثر عرضة للإصابة بأعراض اضطراب فرط الحركة<br />&nbsp; ونقص الانتباه (ADHD) أيضا.</p><p>&bull; قبل وصف هذا الدواء لك، سيقوم طبيبك بشرح ما قد يحدث لطفلك إذا أصبحت حاملاً أثناء تناول<br />&nbsp; الفالبروات. إذا قررت فيما بعد أنك تريدين أن تنجبي طفلاً، يجب عليك عدم التوقف عن تناول الدواء أو<br />&nbsp; عن طريقة تحديد النسل (منع الحمل) حتى تناقشي هذا الأمر مع طبيبك.</p><p>&bull; إذا كنتِ أحد الوالدين أو أحد مقدمي الرعاية لطفلة تعرّضت للفارلبروات، فيجب عليك الاتصال بطبيبها<br />&nbsp; لإخباره عند وصولها لمرحلة البلوغ (بداية الحيض).</p><p>&bull; اسألي طبيبك عن تناول حمض الفوليك عند محاولتك الحمل. يمكن لحمض الفوليك أن يقلل من خطر<br />&nbsp; الإصابة بانشقاق العمود الفقري والإجهاض المبكر الذي قد يحدث مع أي حمل. ومع ذلك، فمن غير<br />&nbsp; المرجح أن يقلل ذلك من خطر حدوث العيوب الخلقية المرتبطة باستخدام فالبروات.</p><p>&nbsp;</p><p><strong>يُرجى اختيار الحالات التي تنطبق عليك وقراءة الأوصاف أدناه:</strong></p><p><strong>&bull; أنا أبدأ العلاج بديباكين كرونو </strong></p><p><strong>&bull; أنا أتناول ديباكين كرونو ولا أُخطط لإنجاب طفل</strong></p><p><strong>&bull; أنا أتناول ديباكين كرونو وأُخطط لإنجاب طفل </strong></p><p><strong>&bull; أنا حامل وأتناول ديباكين كرونو</strong></p><p><strong>&nbsp;</strong></p><p><strong>أنا أبدأ العلاج بديباكين كرونو</strong></p><p>إذا كانت هذه هي المرة الأولى التي يتم بها وصف ديباكين كرونو لك، سيقوم طبيبك بشرح المخاطر على الجنين إذا أصبحتِ حاملاً. بمجرد أن تصبحي قادرة على الإنجاب، سوف تحتاجين إلى التأكد من استخدام طريقة فعّالة لتحديد النسل (منع الحمل) باستمرار دون انقطاع طوال فترة العلاج بديباكين كرونو. تحدثي إلى طبيبك أو طبيب تنظيم الأسرة إذا كنت بحاجة إلى نصيحة بشأن تحديد النسل (منع الحمل).<br /><strong>الرسائل الرئيسية:</strong></p><p>&bull; يجب استبعاد حدوث الحمل قبل بدء العلاج بديباكين كرونو عن طريق إجراء اختبار الحمل، والتأكد من<br />&nbsp; النتيجة من خلال الطبيب. &nbsp;</p><p>&bull; يجب عليك استخدام وسيلة فعّالة لتحديد النسل (منع الحمل) طوال فترة العلاج بديباكين كرونو.</p><p>&bull; يجب عليك مناقشة طرق منع الحمل المناسبة (منع الحمل) مع طبيبك. سيزودك طبيبك بمعلومات عن<br />&nbsp; كيفية منع الحمل، وقد يحيلك إلى أخصائي للحصول على المشورة بشأن تحديد النسل (منع الحمل).</p><p>&bull; يجب أن تحصلي على مواعيد منتظمة (سنوية على الأقل) مع أخصائي من ذوي الخبرة في علاج الصرع.<br />&nbsp; خلال هذه الزيارة، سيتأكد الطبيب من إدراكك وفهمك لجميع المخاطر المتعلقة باستخدام فالبروات أثناء<br />&nbsp; الحمل.</p><p>&bull; أخبري طبيبك إذا كنتِ ترغبين في إنجاب طفل.</p><p>&bull; أخبري طبيبك <strong>فوراً </strong>إذا أصبحتِ حاملاً أو تعتقدين أنك قد تكونين حاملاً.</p><p>&nbsp;</p><p><strong>أنا أتناول ديباكين كرونو ولا أُخطط لإنجاب طفل<br />إ</strong>ذا كنت ستواصلين العلاج بديباكين كرونو ولكنك لا تخططين لإنجاب طفل تأكدي من أنك تستخدمين وسيلة فعّالة لتحديد النسل (منع الحمل) دون انقطاع طوال فترة علاجك بديباكين كرونو. تحدثي إلى طبيبك أو طبيب تنظيم الأسرة إذا كنتِ بحاجة إلى نصيحة بشأن تحديد النسل (منع الحمل).</p><p><strong>الرسائل الرئيسية:</strong></p><p>&bull; يجب عليك استخدام وسيلة فعّالة لتحديد النسل (منع الحمل) أثناء علاجك بديباكين.</p><p>&bull; يجب عليك مناقشة منع الحمل (منع الحمل) مع طبيبك. سيزودك طبيبك بمعلومات عن منع الحمل، وقد<br />&nbsp; يحيلك إلى أخصائي للحصول على المشورة بشأن تحديد النسل (منع الحمل).</p><p>&bull; يجب أن تحصلي على مواعيد منتظمة (سنوية على الأقل) مع أخصائي متخصص في علاج الصرع.<br />&nbsp; خلال هذه الزيارة، سيتأكد الطبيب من إدراكك وفهمك لجميع المخاطر المتعلقة باستخدام فالبروات أثناء<br />&nbsp; الحمل.</p><p>&bull; أخبري طبيبك إذا كنتِ ترغبين في إنجاب طفل.</p><p>&bull; أخبري طبيبك <strong>فوراً </strong>إذا أصبحتِ حاملاً أو تعتقدين أنك قد تكونين حاملاً.</p><p>&nbsp;</p><p><strong>أنا أتناول ديباكين كرونو وأُخطط لإنجاب طفل</strong><br />إذا كنت تخططين لإنجاب طفل، قومي أولاً بتحديد موعد مع طبيبك.<br />&nbsp;</p><p>لا تتوقفي عن تناول ديباكين كرونو أو عن استخدام مانع الحمل حتى تناقشي هذا الأمر مع طبيبك. سوف يقدم لك طبيبك نصائح أكثر.</p><p>&nbsp;</p><p>إن الأطفال الذين يولدون لأمهات خضعن للعلاج بالفالبروات معرضون لخطر الإصابة بالعيوب الخِلقية والمشاكل المتعلقة بالنمو، والتي يمكن أن تكون مُنهكة بشكل خطير. سيحيلك طبيبك إلى أخصائي متخصص في علاج الصرع، بحيث يمكن تقييم خيارات العلاج البديلة في وقت مبكر. يمكن أن يقوم الأخصائي بتطبيق عدة إجراءات بحيث يكون الحمل لديك سلسًا قدر الإمكان، كما يتم تقليل أي مخاطر لديك ولدى طفلك الذي لم يولد بعد قدر الإمكان.</p><p>&nbsp;</p><p>قد يقرر الأخصائي تغيير جرعة ديباكين، أو استبداله بدواء آخر، أو إيقاف العلاج بديباكين قبل الحمل بفترة طويلة - وهذا للتأكد من أن مرضك قد وصل إلى مرحلة الاستقرار.</p><p>&nbsp;</p><p>اسألي طبيبك عن تناول حمض الفوليك عند محاولتك الحمل. &nbsp;يمكن لحمض الفوليك أن يقلل من خطر الإصابة بانشقاق العمود الفقري والإجهاض المبكر الذي يمكن أن يحدث مع أي حمل. ومع ذلك، فمن غير المرجح أن يقلل ذلك من خطر حدوث العيوب الخلقية المرتبطة باستخدام فالبروات.</p><p><strong>الرسائل الرئيسية:</strong></p><p>&bull; لا تتوقفي عن تناول ديباكين كرونو ما لم يخبرك طبيبك بذلك.</p><p>&bull; لا تتوقفي عن استخدام وسائل منع الحمل (منع الحمل) قبل أن تتحدثي مع طبيبك وتتعاوني معه في وضع<br />&nbsp; خطة لضمان التحكم في حالتك والحد من المخاطر التي يتعرض لها طفلك.&nbsp;</p><p>&bull; قومي بتنسيق موعد مع طبيبك. خلال هذه الزيارة، سيتأكد الطبيب من إدراكك وفهمك لجميع المخاطر<br />&nbsp; المتعلقة باستخدام فالبروات أثناء الحمل.</p><p>&bull; سيحاول طبيبك إستبدال ديباكين كرونو بدواء آخر أو إيقاف ديباكين ﻗﺒﻞ أن ﺗﺼﺒحي ﺣﺎﻣﻼً بفترة طويلة.</p><p>&bull; حددي موعدًا عاجلًا مع طبيبك إذا أصبحتِ حاملاً أو تعتقدين أنّك قد تكونين حاملاً.</p><p>&nbsp;</p><p><strong>أنا حامل وأتناول ديباكين كرونو</strong></p><p>لا تتوقفي عن استخدام ديباكين كرونو ما لم يخبرك طبيبك بذلك لأنّ حالتك قد تصبح أسوأ.</p><p>&nbsp;</p><p>قومي بتحديد موعد عاجل مع طبيبك إذا كنتِ حاملاً أو تعتقدين أنّك حاملاً. سوف ينصحك طبيبك أكثر.</p><p>&nbsp;</p><p>يتعرض الأطفال الذين يولدون لأمهات خضعن للعلاج بالفالبروات لخطر الإصابة بالعيوب الخِلقية ومشاكل في النمو يمكن أن تكون مُنهكة بشكل خطير. ستتم إحالتك إلى أخصائي متخصص في علاج الصرع حتى يتم تقييم خيارات العلاج البديلة.</p><p>&nbsp;</p><p>في الظروف الاستثنائية عندما يكون ديباكين كرونو هو الخيار العلاجي الوحيد المتاح أثناء الحمل، ستتم مراقبتك عن كثب لمتابعة كلّ من حالتك الأساسية والتحقق من كيفية تطور نمو الطفل الذي لم يولد بعد. يجب أن تتلقي أنت وشريكك المشورة والدعم فيما يتعلق بالحمل مع استخدام الفالبروات.</p><p>&nbsp;</p><p>اسألي طبيبك عن تناول حمض الفوليك عند محاولتك الحمل. &nbsp;يمكن لحمض الفوليك أن يقلل من خطر الإصابة بانشقاق العمود الفقري والإجهاض المبكر الذي يمكن أن يحدث مع أي حمل. ومع ذلك، فمن غير المرجح أن يقلل ذلك من خطر حدوث العيوب الخلقية المرتبطة باستخدام فالبروات.</p><p><strong>الرسائل الرئيسية:</strong></p><p>&bull; قومي بتحديد موعد عاجل مع طبيبك إذا كنتِ حاملاً أو تعتقدين أنّك قد تكونين حاملاً.</p><p>&bull; لا تتوقفي عن تناول ديباكين كرونو ما لم يخبرك طبيبك بذلك.</p><p>&bull; تأكدي من إحالتك إلى أخصائي متخصص في علاج الصرع لتقييم الحاجة إلى خيارات علاج بديلة.</p><p>&bull; يجب أن تحصلي على استشارة شاملة حول مخاطر استخدام ديباكين كرونو &nbsp;أثناء الحمل، بما في ذلك<br />&nbsp; التشوهات والآثار على النمو عند الأطفال.</p><p>&bull; تأكدي من إحالتك إلى أخصائي للمراقبة السابقة للولادة من أجل اكتشاف حدوث التشوهات المحتملة.</p><p><strong>&nbsp;</strong></p><p><strong>تأكدي من قراءة دليل المرضى الذي ستحصلين عليه من طبيبك. سوف يناقش طبيبك النموذج السنوي للإقرار بالمخاطر وسيطلب منك التوقيع عليه والاحتفاظ به. سوف تتلقين أيضاً &quot;بطاقة المريض&quot; من الصيدلي الخاص بك لتذكيرك بمخاطر استخدام فالبروات أثناء الحمل.</strong></p><p>&nbsp;</p><p><strong>قد يسبب فالبروات لدى حديثي الولادة للأمهات الذين تناولوا فالبروات أثناء الحمل ما يلي:</strong></p><p>&bull; مشاكل تخثر الدم (مثل عدم تخثّر الدم بشكل جيّد للغاية). قد يظهر هذا على شكل كدمات أو النزيف<br />&nbsp;&nbsp;الذي يستغرق وقتًا طويلاً للتوقف.</p><p>&bull; نقص سكر الدم (انخفاض السكر في الدم).</p><p>&bull; قصور الغدة الدرقية (الغدة الدرقية غير النشطة، والتي يمكن أن تسبب التعب أو زيادة الوزن).</p><p>&bull; متلازمة الانسحاب (بما في ذلك الانفعالية، الهيجان، فرط الاستثارة، العصبية، فرط الحركة، مشاكل<br />&nbsp; العضلات، الرعاش، التشنجات ومشاكل التغذية). وعلى وجه الخصوص، قد تحدث هذه الأعراض لدى<br />&nbsp; الأطفال حديثي الولادة الذين تناولت أمهاتهم فالبروات خلال الأشهر الثلاثة الأخيرة من الحمل.</p><p>&nbsp;</p><p><strong>الرضاعة الطبيعية</strong></p><p>قد يُفرز ديباكين كرونو بكميات قليلة جداً في حليب الثدي. ومع ذلك عليك استشارة الطبيب لمعرفة إذا كان بإمكانك إرضاع طفلك طبيعياً. إستشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد تشعر بالنّعاس أثناء استخدام هذا الدواء. إذا حدث ذلك، تجنب القيادة واستخدام الآلات والأدوات. قد يزيد استخدام ديباكين كرونو مع الأدوية الأخرى المضادة للصرع أو أدوية الأمراض النفسية من حدوث النّعاس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب استخدام ديباكين كرونو حسب ارشادات الطبيب دائماً. اسأل طبيبك إذا لم تكن مُتأكداً.<br /><br />ينبغي أن يخضع العلاج بديباكين منذ بدايته للإشراف الطبي من قبل طبيب مُتخصّص بعلاج الصرع.</p><p>&nbsp;</p><p><strong>تناول هذا الدواء:</strong></p><p>&bull; سيُحدد لك طبيبك أو لطفلك الجرعة تبعاً لوزنك أو وزن طفلك.</p><p>&bull; تناول هذا الدواء عن طريق الفم.</p><p>&bull; <strong>لا تقم</strong> بسحق أو مضغ الأقراص.</p><p>&bull; إذا شعرت أنّ تأثير هذا الدواء ضعيف جداً أو قوي جداً، لا تقم بتغيير جرعة الدواء من تلقاء نفسك،<br />&nbsp; استشر طبيبك.<br />&nbsp;</p><p><strong>طريقة تناول الدواء</strong><br />&bull; يمكن تناول جرعة هذا الدواء إما مرة واحدة أو على جزئين يومياً.<br />&nbsp;</p><p><strong>جرعة الدواء<br />البالغين (بما فيهم كبار السنّ)</strong><br />&bull; الجرعة الابتدائيّة 600 مجم في اليوم. ينبغي أن يقوم طبيبك بزيادة الجرعة بمقدار 200 مجم كل 3<br />&nbsp; أيام تبعاً لحالتك.</p><p>&bull; تتراوح الجرعة اليومية المُعتادة بين 1000 مجم و 2000 مجم (20-30 مجم لكل كجم) في اليوم.</p><p>&bull; يمكن زيادة الجرعة إلى 2500 مجم في اليوم تبعاً لحالتك.</p><p><strong>&nbsp;</strong></p><p><strong>الأطفال ممن تتجاوز أوزانهم 20 كجم </strong></p><p>&bull; الجرعة الابتدائيّة 400 مجم في اليوم. ينبغي أن يقوم طبيبك بزيادة الجرعة تبعاً لحالة طفلك.<br />&bull; تتراوح الجرعة المعتادة بين 20-30 مجم لكل كجم في اليوم.</p><p>&bull; يمكن زيادة الجرعة اليوميّة إلى 35 مجم لكل كيلوغرام من وزن الجسم، اعتمادا على مرض طفلك.</p><p><strong>&nbsp;</strong></p><p><strong>الأطفال ممن تقل أوزانهم عن 20 كجم</strong></p><p>لا يُنصح باستخدام ديباكين كرونو لدى الأطفال الذين تقل أوزانهم عن 20 كجم، ويُنصح باستخدام ديباكين السائل (الخالي من السكر) أو شراب ديباكين عوضاً عن ذلك.</p><p><strong>&nbsp;</strong></p><p><strong>المرضى ممن يعانون من مشاكل في الكلى </strong></p><p>&bull; قد يُقرر طبيبك تعديل جرعة الدواء لك أو لطفلك.</p><p><strong>&nbsp;</strong></p><p><strong>المرضى الذين يتناولون أدوية أخرى مضادة للصرع</strong></p><p>&bull; ﻗد ﺗﺗﻧﺎول أﻧت أو طﻔﻟك أدوﯾﺔ أﺧرى مُضادة ﻟﻟﺻرع ﻓﻲ ﻧﻔس اﻟوﻗت مع دﯾﺑاﮐﯾنكرونو . إذا كان الأمر<br />&nbsp; كذلك، يجب على الطبيب أن يبدأ العلاج تدريجيًا وفقًا لحالتك أو حالة طفلك.</p><p>&bull; قد يزيد طبيبك جرعة ديباكين كرونو بمقدار 5-10 مجم لكل كيلوغرام من وزن الجسم كل يوم حسب نوع<br />&nbsp; الأدوية الأخرى التي تتناولها.</p><p><br />&nbsp;</p><p><strong>إذا تناولت من ديباكين كرونو أكثر مما يجب:</strong></p><p>إذا تناولت من ديباكين كرونو أكثر مما يجب، قم على الفور بإبلاغ الطبيب أو اذهب لقسم الخدمات الطبية الطارئة في المستشفى على الفور. خذ معك علبة الدواء كي يُلمّ الطبيب بما تناولت.</p><p>&nbsp;</p><p>قد تحدث الأعراض التالية: الشعور بالمرض أو حدوثه، تقلّص حجم بؤبؤ العين، الدوخة، فقدان الوعي، ضعف العضلات واضطراب في ردود الأفعال، مشاكل في التنفس، صداع، تشنّجات (نوبات) الارتباك، فقدان الذاكرة سلوك غير معتاد أو غير لائق.</p><p>&nbsp;</p><p><strong>إذا نسيت أن تتناول ديباكين كرونو:</strong></p><p>إذا نسيت أن تتناول إحدى الجرعات، تناولها بمجرد أن تتذكر. ولكن إذا تذكرت الجرعة الفائتة قبل موعد الجرعة اللاحقة بوقت قصير، تجاوز الجرعة الفائتة. لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول ديباكين كرونو:</strong></p><p>ينبغي أن تستمر في تناول الدواء إلى أن يخبرك الطبيب بالتوقف. لا تتوقف عن تناول الدواء لمجرد أنّك تشعر بالتحسّن. قد يؤدي توقفك عن تناول الدواء إلى ظهور النوبات مرة أخرى.</p><p>&nbsp;</p><p><strong>الفحوصات الطبيّة</strong></p><p>تأكد من تنسيق مواعيد منتظمة لك أو لطفلك للكشف الطبي. الانتظام في حضور هذه المواعيد مهم جدًا إذ قد تحتاج إلى تغيير في الجرعة أنت أو طفلك. يمكن أن يؤدي تناول ديباكين كرونو إلى تغيير في مستويات انزيمات الكبد التي تظهر في فحوصات الدم. قد يعني ذلك أن الكبد لديك أو لدى طفلك لا يعمل بشكل صحيح. إذا ذهبت أنت أو طفلك إلى المستشفى أو قمت بزيارة أي طبيب آخر أو طبيب أسنان، أخبرهم أنك تتناول ديباكين كرونو.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع سائر الأدوية، يمكن أن تُسبب أقراص ديباكين كرونو آثاراً جانبية، وإن كانت لا تحدث لدى جميع من يتناولها.</p><p><strong>أخبر طبيبك على الفور إذا تعرّضت لأي من الأعراض الجانبية الخطيرة التالية &ndash; قد تحتاج إلى رعاية طبية سريعة:</strong></p><p>&bull; <strong>رد فعل تحسسي</strong>. قد تشتمل العلامات على: طفح جلدي، ألم مفصلي، حمى (ذئبة حمامية جهازية)،<br />&nbsp; مشاكل في البلع أو التنفس، تورم في شفاهك، أو وجهك، أو حلقك أو لسانك. قد تتأثر أيضا اليدين أو<br />&nbsp; القدمين أو الأعضاء التناسلية. يمكن أن تؤدي تفاعلات الحساسية الأكثر حدة إلى تضخّم العقد الليمفاوية<br />&nbsp; واحتمالية ضعف الأعضاء الأخرى.</p><p>&bull; قد تظهر مشاكل الكبد ومشاكل البنكرياس كمرض مفاجئ يظهر خلال الأشهر الستة الأولى من العلاج.<br />&nbsp; يحدث ذلك في عدد قليل جدًا من الأشخاص الذين يتناولون ديباكين كرونو. وتشمل الأعراض الشعور<br />&nbsp; المُتكرر بالمرض وحدوث المرض؛ الشعور بالتعب، والنعاس والضعف؛ آلام في المعدة بما في ذلك ألم<br />&nbsp; شديد في البطن وعلى الأخص في الجزء العلوي من البطن؛ اليرقان (اصفرار الجلد أو بياض العين)؛ فقدان<br />&nbsp; الشهية؛ تورم (خاصة في الساقين والقدمين ولكن قد يشمل أجزاء أخرى من الجسم)؛ تفاقم النوبات لديك أو<br />&nbsp; الشعور العام بالتوعك. قد يطلب منك طبيبك التوقف عن تناول ديباكين كرونو على الفور إذا كنت تعاني<br />&nbsp; من هذه الأعراض.</p><p>&bull; ظهور طفح جلدي أو آفات جلدية لديك ذات حلقات حمراء/وردية، لها مراكز باهتة اللون والذي قد يكون<br />&nbsp; حاكًّا أو متقشرًا أو مملوءًا بالسوائل. قد يظهر الطفح بشكل خاص على الراحتين أو باطن القدمين. قد<br />&nbsp; تكون هذه علامات حساسية خطيرة للدواء تُسمى &quot;حمامي عديدة الأشكال&quot;.</p><p>&bull; تقرحات أو نزيف الجلد حول الشفاه والعيون والفم والأنف والأعضاء التناسلية. وكذلك أعراض تشبه أعراض<br />&nbsp;&nbsp;الإنفلونزا والحمى. قد يكون ذلك اضطراباً يُسمّى &quot;متلازمة ستيفنز جونسون&quot;.</p><p>&bull; طفح جلدي حاد تتقشّر معه طبقات الجلد لتترك مساحات كبيرة من الجلد المكشوف على الجسم. كذلك<br />&nbsp; الشعور العام بالتوعك، والحمى، وقشعريرة وآلام العضلات. قد يكون ذلك اضطراباً يسمى &quot;انحلال البشرة<br />&nbsp; النخري السمي&quot;.</p><p>&bull; ظهور الكدمات بسهولة أكبر والتعرّض للعدوى أكثر من المعتاد. قد يدل ذلك على مشكلة في الدم تُسمى<br />&nbsp; &quot;قلة الصفيحات&quot;. كما قد يحدث ذلك أيضاً بسبب انخفاض عدد خلايا الدم البيضاء، أو كبت نخاع العظم &nbsp;<br />&nbsp; أو حالة أخرى تؤثر على خلايا الدم الحمراء، وخلايا الدم البيضاء والصفائح الدموية (قلّة الكريات الشاملة)<br />&nbsp; أو على كيفية تجلط الدم.</p><p>&bull; اضطرابات تخثر الدم (النزيف لفترة أطول من المعتاد)، كدمات أو نزيف بدون سبب.</p><p>&bull; التغيرات في المزاج، وفقدان الذاكرة، وعدم التركيز وفقدان الوعي العميق (غيبوبة).</p><p>&bull; قلة نشاط الغدة الدرقية، والتي قد تسبب الشعور بالتعب أو زيادة الوزن (قصور الغدة الدرقية).</p><p>&bull; صعوبة في التنفس وألم بسبب التهاب في الرئتين (الانصباب الجنبي).</p><p>&nbsp;</p><p><strong>أخبر طبيبك في أقرب وقت ممكن إذا تعرضت لأي من الأعراض الجانبية التالية:</strong></p><p>&bull; التغييرات في السلوك بما في ذلك التيقظ الشديد، وأحيانا العدوانية أيضاً، وفرط النشاط &nbsp;وسلوك غير عادي<br />&nbsp; أو غير مناسب. يزداد احتمال حدوث هذا عند تناول ديباكين كرونو مع أدوية أخرى مُضادة للصرع مثل<br />&nbsp; الفينوباربيتال وتوبيراميت في نفس الوقت أو إذا كانت الجرعة الابتدائية مرتفعة أو عند زيادتها بشكل<br />&nbsp; مفاجىء.</p><p>&bull; التغيرات في كمية الأمونيا في الدم. وتشمل أعراض هذه الحالة مرضية، الشعور بالمرض، اضطراب في<br />&nbsp; التوازن والتنسيق، أو الشعور بالخمول أو تدني مستوى اليقظة.</p><p>&bull; الشعور بالارتعاش (رعاش)، والنعاس أو عدم الثبات عند المشي أو حركة العضلات النّفضية.</p><p>&bull; الشعور بالإرهاق أو الارتباك مع فقدان الوعي الذي يكون مصحوباً أحيانًا بهلوسة أو نوبات.</p><p>&bull; بثور جلدية مع تقشر الجلد.</p><p>&bull; حركة للعيون سريعة، يصعب السيطرة عليها.</p><p>&bull; زيادة في عدد وشدة التشنجات.</p><p>&nbsp;</p><p><strong>أخبر طبيبك أو الصيدلي إذا تفاقم أي من الأعراض الجانبية التالية أو إذا استمرت لأكثر من بضعة أيام، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة:</strong></p><p>&bull; الشعور بالمرض (الغثيان) أو حدوث المرض (التقيؤ) أو آلام المعدة أو الإسهال خاصة عند بدء العلاج.<br />&nbsp; قد تقل هذه الأعراض عن طريق تناول الأقراص مع الطعام.</p><p>&bull; تورم اللثة أو تقرح الفم.</p><p>&bull; الإغماء</p><p>&bull; فقدان السمع</p><p>&bull; اضطرابات الأظافر وبطانتها</p><p>&bull; مشاكل الجلد مثل الطفح الجلدي. تحدث هذه الأعراض نادرا، لكنها تحدث في كثير من الأحيان لدى<br />&nbsp; المرضى الذين يتناولون لاموتريجين في نفس الوقت.</p><p>&bull; حب الشباب</p><p>&bull; تساقط الشعر عادة ما يكون مؤقتًا. عندما ينمو مرة أخرى قد يكون أكثر تجعيدا من ذي قبل.</p><p>&bull; اضطرابات الشعر (تغيرات في الملمس أو اللون أو النمو)</p><p>&bull; زيادة في مستويات بعض الهرمونات (الأندروجينات)، مما قد يؤدي إلى زيادة نمو الشعر على الوجه أو<br />&nbsp; الصدر أو الصدر أو حب الشباب أو ترقّق الشعر.</p><p>&bull; الطفح الجلدي الناجم عن تضيّق أو انسداد الأوعية الدموية (التهاب الأوعية الدموية)</p><p>&bull; التغيرات في الحيض وزيادة نمو الشعر لدى النساء</p><p>&bull; تضخّم الثدي لدى الرجال</p><p>&bull; تورم في القدمين والساقين (وذمة)</p><p>&bull; زيادة الوزن &ndash; إذا قد تزداد الشهية لديك.</p><p>&bull; مرض الكلية</p><p>&bull; مشاكل الكلى، التبول اللاإرادي أو زيادة في الحاجة لإخراج البول</p><p>&bull; ظهور الدم في البول</p><p>&bull; صداع</p><p>&bull; رؤية أو سماع أشياء غير موجودة (هلوسة)</p><p>&bull; العدوانية، والإثارة، والاضطراب في الانتباه، والسلوك غير الطبيعي، والأرق/فرط النشاط، واضطراب التعلم.</p><p>&bull; وخز أو تنميل في اليدين والقدمين</p><p>&bull; انخفاض درجة حرارة الجسم الطبيعية</p><p>&bull; عوامل تخثر الدم غير طبيعية</p><p>&bull; آلام العضلات وضعفها (انحلال الربيدات)</p><p>&bull; بدانة</p><p>&nbsp;</p><p><strong>اضطرابات العظام</strong></p><p>هناك تقارير عن حدوث اضطرابات العظام بما في ذلك انخفاض الكثافة العظمية وهشاشة العظام (ترقق العظام) والكسور. استشر طبيبك أو الصيدلي إذا كنت تتناول الأدوية المضادة للصرع على المدى الطويل، أو لديك تاريخ من الإصابة بهشاشة العظام، أو تناول الستيروئيدات.</p><p>&nbsp;</p><p><strong>تحاليل الدم</strong></p><p>يمكن أن يسبب ديباكين كرونو تغيير في مستويات إنزيمات الكبد أو الأملاح أو السكريات التي تظهر في اختبارات الدم والبول.</p><p>&nbsp;</p><p><strong>الخصوبة لدى الذكور</strong></p><p>يمكن أن يساهم &nbsp;تناول ديباكين كرونو في حدوث العقم لدى الذكور.</p><p>&nbsp;</p><p><strong>للإبلاغ عن الآثار الجانبية</strong><br />* المملكة العربيّة السعوديّة</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:26.65pt;width:478.5pt;height:179.5pt;z-index:251663360;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEApddVCSkFAADRHwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWd1u2zYUvh+wdyB0OziW/xOjTue4
TdEiW4O4fQCaom0iFKWR9E961ybdgjxFm61NE2woul5su91TSG+zQ0p2bLdJi8YpkEEWwvDn6Ojw
O5+OyMNbt8c+R0MqFQtEwymsuA6iggQeE72G8/jRZm7VQUpj4WEeCNpw9qhybq9/+80tXO9JHPYZ
QaBBqDpuOH2tw3o+r0if+litBCEVMNYNpI81NGUv70k8As0+zxddt5r3MRPO+rmqO1hjNJDsC1Tx
gOxSr4XFECtQyUl9tie1kZOra8Z1Mbwnw3a4LY3l5MfhtkTMaziAnMA+QOTk04FUDJr5hbt65wrG
Xekb+aDbReOGs1Yol11QtQfOKKxVam4lUUfHGhEYr7q16loFBAhIFIu1tSo0kgf2H16ugvTvfkIJ
mJmYA5UZE1VoDBTDD+dcKkwm/cgYuBGMUXE6fSOO9Bg6YS7WzSrcAjcpJIJWH4sebUoZjPoUe8pI
JDgBoMlzLGaTRyqjqzP6IfAAYDzQgdW3JOym08b1UCp9jwY+MpWGIynR9kl4uKV0YuBExGCiAs68
Tca5bchep8UlGmLecDbtL53TnBgXaAR+rhQrCSYXqnDt72MqfKapRJz5DWd1KoTrBsm7wrNs0Jjx
pA6z48JS0IBoDNXjtvWo8Y23Z3o68B8AlgHMGbgF8QAq/UA+cdAI3vKGo34aYEkdxO8L8JUlqYO0
bZQrtSLcI2dHOrMjWBBQ1XC0g5JqS0PLtbMXQROc2WUptokdxiKudFvvcWonY601DPCx3LIWQmXH
VjDvQdyS8HwNqCc046IdEuuRkGwTnTik4NYAqhTNWYkN2p3IapXITsRUSM5Hm129KAfgT9wTEjsO
YKcgW6Ql2MyB6cBZmWs3IZQ+ASPNC25U0W4X+JUQC2aMNRNI74W0iwmwvIU560jmoBCLQEGHW3Q3
3QqU5iq7JVPCKNOkv4l9xiEglKCD9LFU1DrSgkfxNSglakZpm/khZ11GPdSUuMPInM1Ftwq2VsBi
Y3vpA5sL8IWZ2pyrraaIAnQGI70encQH8fPoXbwf/Yls4zD6K/45PkLQfxCdxUfxs+hvFB+aseg9
/J2A+KkVjd6a7uh1fBSdmiAMHoTSKu5kDkpJdRUHAZopkMZZGd3Nq3k1usdPgb/70fs6QvFJ/Bqu
41x8HL+IX+Xil/HLXHxqOr/L2HwN4SZj87KDd/wLhN+z+Klh8xugMVwJm3/N2Jx85q/v45mxedls
js6iP+JDWHAcRKfAaFQsFWq5YqlSNUXJFGUoSqYou1mEziL0l67Zv/byOo3SyfL6efQ7LEFggV03
MfsFXMfxb7DsMDW4Ml5nvL4hvI7ewLbxKHqb7AVfwX5xH0L4Owjhlt0LTF7YEFKRe9ye2bGjAaRB
RM+xSYCLkzaVaqk1yWXN5X0u3+0vfxkA+YVr3/k3JcN8bre/AdufMmyCJtfnZCj6nIndFmdkN83T
Qnro07lkSJgyQu8EZOBToZOEsqQmixII1WehgpxQ3SRm5X1v4pBpUkGEZMWTg973quvhlV4wXFF4
gQ4fSRA8ePjV+JBlf2yq5qLkwpwnslzaJP/3ebk0iH/Pon+yoLi8HOvceu2mBEV7UmPSoZNM62g0
WpmJh3kIkgsxkQpvG0u8M01rz34kC/+ztPYy/AjwnmNmI1pylmFC1s0+0Mg8f/nBy+yL9e/8pgmG
gAVQnh/ADRRthztwGpScMSYndCBhjl7zC4fZ9tb08N2cmM+21/8DAAD//wMAUEsDBBQABgAIAAAA
IQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1js
vbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqObkVy6qVAgbTooQF666EoGqABGvTSH2PAQZv+iA65
L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWOMReExW2/eqviezgesTGJg7b/aLD92W3fExLFY0RZ
jNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSLddT2QymT9ZUVMQIyErdYgmN4NmE8QhJuebAy5ugE
Fojoymql0lyJEIn9DZAolaAehX+xFIoworyvxGAvRhGsfjCZkBHW2PFRVSHETHQp944Rbfsgc8xO
BviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3rf8yvoxhfLSq1+TBsFi0Xm/Um5uFfA2gchHXa/Wa
vWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZWrWrhDfm1BZ03G+pn4TUolV9fwG9vd8GKFl6DUnxj
Ad/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0gK40mrVuvtsCMmF0xwlfa9S3W6uZ8BIF0VBEl1pi
wmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJkBNvlwQhBF6CYiaAXFmtbFdq8F/96vpKexStY2Rw
K71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785ff776YsXp89/zdbWoiy+HRQHJt/7n77559WX3t+/
/fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPvXr978/rs+6//+vmlQ/omR0MTPiARFt4+PvEesgg2
6NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+GKHLgOti242MOqcYFvDd9aincD/lUEofEB2FkAfcY
ox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx5eXeNIEcS1wiuyG21DykKJYowDGWnnrGjjB27O4J
IZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tgl5lLQfC3ZZu9x16HUdeut/CxjYR3A1GH8gNMLTPe
Q1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT5vXGWAgXzwGH/RpOfwBpxu32PTqLbCSX5Mglcxcx
ZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY/Yaoe/ADipe6+zHBlrvPzwaPIMOaKpUBop5MucOX
9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYuxhSdoDHG3qPPHRp0WGLZvFT6fghZZQe7Aus+smNV
3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYojxJdJ3gevmzbvQamLXAFwQEdHJnCfQL8H8eI0yoEA
GUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5YaF3gvgQdfmgcSu8nzQdsMELUWKANmgKDLcKVbYLHc
X7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+jf+u94EO4+yHV46X7Xr6HbdgK1ldstNZlkx25vqb
Zbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa/3/f0yx7n286mWX9xk0n40OHcdPJZMOV6+lkyuYF
+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z8TYQFZ+ebuJiCpiEcKnKHCxg4QKONI/HmfyCyLAf
ogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPjdNhZrarBZlpZBZIlvdIo6DCokim62SoHeIV4rW2g
B625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEronV2LFmsOLW4r8bmrFrQA1QqvwAe3B5/pbb9RBxZg
gnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSUnl5Tui7dntpdGmoX8LSlhBFuthLaMrrBEyF8BmfR
qagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1NfDN5wYam5mCxt5J22/WGhAyI5S0/QkMjeEySiB2
hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNmg4hIzD1Koravtl+4gcY6h2jdqquQED5a5dYgrXxs
yoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86WHGyKbi7H45PvCGd8ocIQqzRqioDjomAs4Nqas0x
gcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnMU7hO5YU6+q6wgXGX7RkMapgkK4TDQBVY06hWNS2q
RqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNztrxakTe0yk0MOc2s8Gnqnk+5a3mum+sTiioBBi/s
56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNUu0iRMLJ+Mxc7Z7eiRjiXA+KVKj/wzUctkCZ5X6kt
7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0qGlzBmTOUi/SguO1nFzkFnqeUAlPLKbUcU88p9ZzS
yCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBmvYV9+r/xLwAAAP//AwBQSwMEFAAGAAgAAAAhACDt
hzv+AAAAdQIAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHO0
0s1KAzEQB/C74DuEuZvsVhApzdaDCj14kfoAQzKbDd18kKTd9u0NVLGFFi96CeTrP78JWSz3bmQ7
StkGL6HlDTDyKmjrjYSP9evdI7Bc0GscgycJB8qw7G5vFu80YqmX8mBjZjXFZwlDKXEuRFYDOcw8
RPJ1pw/JYanTZEREtUFDYtY0DyKdZkB3lslWWkJa6Xtg60OslX/PDn1vFT0HtXXky4USolQX1UBM
hooEzo8rx7Hl1QriMmP2l4yhNpRG6zc/lK/upmniudfITdjxjMJH9X3mLej6Ci/7QsnjVWf7z06H
dixhXl1cp615OsFeh4qzz9J9AgAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAA
AAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAA
MgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAKXXVQkpBQAA
0R8AAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwEC
LQAUAAYACAAAACEAkn2H4B0HAABJIAAAGgAAAAAAAAAAAAAAAACGBwAAY2xpcGJvYXJkL3RoZW1l
L3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAIO2HO/4AAAB1AgAAKgAAAAAAAAAAAAAAAADbDgAA
Y2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEA
ACEQAAAAAA==
">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-right:-3.7pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:14.0pt;
    line-height:107%;font-family:"Simplified Arabic",serif'>المركز الوطني
    للتيقظ والسلامة الدوائية<br>
    فاكس:<span style='mso-spacerun:yes'>  </span>٧٦٦٢-٢٠٥-١١-٩٦٦+<br>
    هاتف:<span style='mso-spacerun:yes'>  </span>٨٢٢٢-٢٠٣-١١-٩٦٦+<br>
    تحويلة:<span style='mso-spacerun:yes'>   </span>2317-2356-2353-2354-2334-2340<br>
    الهاتف المجاني: ٨٠٠٢٤٩٠٠٠٠<br>
    البريد الإلكتروني: </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    dir=LTR style='font-size:14.0pt;line-height:107%;font-family:"Simplified Arabic",serif;
    mso-bidi-language:AR-JO'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span lang=AR-JO style='font-size:14.0pt;line-height:
    107%;font-family:"Simplified Arabic",serif;mso-bidi-language:AR-JO'><br>
    </span></span><span lang=AR-JO style='font-size:14.0pt;line-height:107%;
    font-family:"Simplified Arabic",serif;mso-bidi-language:AR-JO'>الموقع
    الإلكتروني: </span><a href="http://www.sfda.gov.sa/npc"><span dir=LTR
    style='font-size:14.0pt;line-height:107%;font-family:"Simplified Arabic",serif;
    mso-bidi-language:AR-JO'>www.sfda.gov.sa/npc</span></a><span lang=AR-JO
    style='font-size:14.0pt;line-height:107%;font-family:"Simplified Arabic",serif;
    mso-bidi-language:AR-JO'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='mso-bidi-language:AR-JO'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="644" height="245" alt="Text Box: المركز الوطني للتيقظ والسلامة الدوائية
فاكس:  ٧٦٦٢-٢٠٥-١١-٩٦٦+
هاتف:  ٨٢٢٢-٢٠٣-١١-٩٦٦+
تحويلة:   2317-2356-2353-2354-2334-2340
الهاتف المجاني: ٨٠٠٢٤٩٠٠٠٠
البريد الإلكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa/npc

" src="file:///C:/Users/sa000797/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />سانوفي &ndash; التيقّظ :<strong> </strong>KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p>لا ينبغي استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد على العبوة.</p><p>يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>احفظه في درجة حرارة أقل من 30 درجة مئوية، في مكان جاف بعيداً عن الرطوبة.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماذا تحتوي أقراص ديباكين كرونو 500 مجم مديدة التحرّر المُحزّزة والمُغلّفة بغشاء رقيق </strong></p><p><strong>المادة الفعالة:</strong></p><p>صوديوم فالبروات .................&nbsp; 333 مجم</p><p>حمض الفالبرواك .................&nbsp; 145 مجم<br />مقدار يعادل من الصوديوم فالبروات 500 مجم&nbsp;&nbsp;<br />في كل قرص مُحزّز ومُغلف بغشاء رقيق</p><p>&nbsp;</p><p><strong>المكوّنات الأخرى هي: </strong><br />إيثيل السيليلوز 20 mPa.s، هايبروميلوز 3000 mPa.s، السيليكا الغروية اللامائية، السيليكا الغروية المائية، صوديوم سكارين، هايبروميلوز 6 mPa.s ، ماكروغول 6000 ، بولي أكريلات مُبعثر 30% (EUDRAGIT&reg; E30D) ، التالك، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            ما هو الشكل الصيدلاني لأقراص ديباكين كرونو ووصفها وحجم عبوتها
يتوفر هذا الدواء على شكل أقراص مُحززة مُغلّفة بغشاء رقيق في عبوات تحتوي على 30، 40، 60، أو 100 قرص. 

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><u>مالك رخصة التسويق</u></p><p>سانوفي-أفنتيس فرنسا</p><p>82، طريق راسباي<br />94250 جنتلي - فرنسا</p><p>&nbsp;</p><p><u>المُصنّع</u></p><p>سانوفي-أفنتيس، S.A.الصناعيّة<br />33565 كربون بلانك &ndash; فرنسا<br />&nbsp;</p><p><u>التغليف الثانوي</u></p><p>شركة سانوفي أفنتيس العربية المحدودة، الوادي الصناعي المرحلة الأولى 1A St.، مدينة الملك عبد الله الاقتصادية- KAEC، رابغ، 21423، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 DEPAKINE CHRONO® 500 mg prolonged-release scored film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Constituents
Each tablet contains 333 mg Sodium Valproate and 145 mg Valproic Acid equivalent to 500 mg sodium valproate.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Prolonged-release scored film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of generalised, partial or other epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Depakine Chrono Controlled Release Tablets are for oral administration.</p><p>Depakine Chrono is a prolonged release formulation of Depakine which reduces peak concentration and ensures more even plasma concentrations throughout the day.</p><p>Depakine Chrono 500 may be given once or twice daily. The tablets should be swallowed whole and not crushed or chewed.</p><p>Daily dosage requirements vary according to age and body weight.</p><p>In patients where adequate control has been achieved Depakine Chrono formulations are interchangeable with other Depakine conventional or prolonged release formulations on an equivalent daily dosage basis.</p><p><em>Dosage</em></p><p>Usual requirements are as follows:</p><p><u>Adults</u></p><p>Dosage should start at 600 mg daily increasing by 200 mg at three-day intervals until control is achieved. This is generally within the dosage range 1000 mg &ndash; 2000 mg per day, i.e. 20 &ndash; 30 mg/kg/day body weight. Where adequate control is not achieved within this range the dose may be further increased to 2500 mg per day.</p><p><u>Children over 20 kg</u></p><p>Initial dosage should be 400 mg/day (irrespective of weight) with spaced increases until control is achieved; this is usually within the range 20 &ndash; 30 mg/kg body weight per day.</p><p>Where adequate control is not achieved within this range the dose may be increased to 35 mg/kg body weight per day.</p><p><u>Children under 20 kg</u></p><p>An alternative formulation of Depakine should be used in this group of patients, due to the tablet size and need for dose titration. Depakine Liquid (sugar-free) or Depakine Syrup are alternatives.</p><p><u>Elderly</u></p><p>Although the pharmacokinetics of Depakine are modified in the elderly, they have limited clinical significance and dosage should be determined by seizure control. The volume of distribution is increased in the elderly and because of decreased binding to serum albumin, the proportion of free drug is increased. This will affect the clinical interpretation of plasma valproic acid levels.</p><p><u>In patients with renal insufficiency</u></p><p>It may be necessary to decrease the dosage. Dosage should be adjusted according to clinical monitoring since monitoring of plasma concentrations may be misleading (see section 5.2 Pharmacokinetic Properties).</p><p><u>In patients with hepatic insufficiency</u></p><p>Salicylates should not be used concomitantly with Depakine since they employ the same metabolic pathway (see also sections 4.4 Special Warnings and Precautions for Use and 4.8 Undesirable Effects).</p><p>Liver dysfunction, including hepatic failure resulting in fatalities, has occurred in patients whose treatment included valproic acid (see sections 4.3 Contraindications and 4.4 Special Warnings and Precautions for Use).</p><p>Salicylates should not be used in children under 16 years (see aspirin/salicylate product information on Reye&#39;s syndrome). In addition in conjunction with Depakine, concomitant use in children under 3 years can increase the risk of liver toxicity (see section 4.4.1 Special warnings).</p><p><u>Female children and women of childbearing potential</u></p><p>Valproate must be initiated and supervised by a specialist experienced in the management of epilepsy. Valproate should not be used in female children and women of childbearing potential unless other treatments are ineffective or not tolerated (see sections 4.3, 4.4 and 4.6)</p><p>Valproate is prescribed and dispensed according to the Valproate Pregnancy Prevention Programme (see sections 4.3 and 4.4). The benefits and risks should be carefully reconsidered at regular treatment reviews (see section 4.4).</p><p>Valproate should preferably be prescribed as monotherapy and at the lowest effective dose, if possible as a prolonged release formulation. The daily dose should be divided into at least two single doses (see section 4.6).</p><p><u>Combined Therapy</u></p><p>When starting Depakine in patients already on other anti-convulsants, these should be tapered slowly; initiation of Depakine therapy should then be gradual, with target dose being reached after about 2 weeks. In certain cases it may be necessary to raise the dose by 5 &ndash; 10 mg/kg/day when used in combination with anti-convulsants which induce liver enzyme activity, e.g. phenytoin, phenobarbital and carbamazepine. Once known enzyme inducers have been withdrawn it may be possible to maintain seizure control on a reduced dose of Depakine. When barbiturates are being administered concomitantly and particularly if sedation is observed (particularly in children) the dosage of barbiturate should be reduced.</p><p>NB: In children requiring doses higher than 40 mg/kg/day clinical chemistry and haematological parameters should be monitored.</p><p>Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. However, a method for measurement of plasma levels is available and may be helpful where there is poor control or side effects are suspected (see section 5.2 Pharmacokinetic Properties).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Depakine is contraindicated in the following situations:
• In pregnancy unless there is no suitable alternative treatment (see section 4.4 and 4.6).
• In women of childbearing potential unless the conditions of the pregnancy prevention programme are fulfilled (see sections 4.4 and 4.6).
• Active liver disease.
• Personal or family history of severe hepatic dysfunction, especially drug related.
• Patients with known urea cycle disorders (see section 4.4).
• Hypersensitivity to sodium valproate.
• Porphyria.
• Valproate is contraindicated in patients known to have mitochondrial disorders caused by mutations in the nuclear gene encoding the mitochondrial enzyme polymerase γ (POLG), e.g. Alpers-Huttenlocher Syndrome, and in children under two years of age who are suspected of having a POLG-related disorder (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although there is no specific evidence of sudden recurrence of underlying symptoms following withdrawal of valproate, discontinuation should normally only be done under the supervision of a specialist in a gradual manner. This is due to the possibility of sudden alterations in plasma concentrations giving rise to a recurrence of symptoms. NICE has advised that generic switching of valproate preparations is not normally recommended due to the clinical implications of possible variations in plasma concentrations.</p><p><strong>4.4.1 Special warnings </strong></p><p><strong><em>Liver dysfunction:</em></strong><strong> </strong></p><p><u>Conditions of occurrence</u>:</p><p>Severe liver damage, including hepatic failure sometimes resulting in fatalities, has been very rarely reported. Experience in epilepsy has indicated that patients most at risk, especially in cases of multiple anti-convulsant therapy, are infants and in particular young children under the age of 3 years and those with severe seizure disorders, organic brain disease, and (or) congenital metabolic or degenerative disease associated with mental retardation. After the age of 3 years, the incidence of occurrence is significantly reduced and progressively decreases with age.</p><p>The concomitant use of salicylates should be avoided in children under 3 years due to the risk of liver toxicity. Additionally, salicylates should not be used in children under 16 years (see aspirin/salicylate product information on Reye&#39;s syndrome).</p><p>Monotherapy is recommended in children under the age of 3 years when prescribing Depakine, but the potential benefit of Depakine should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of therapy</p><p>In most cases, such liver damage occurred during the first 6 months of therapy, the period of maximum risk being 2 &ndash; 12 weeks.</p><p><u>Suggestive signs</u>:</p><p>Clinical symptoms are essential for early diagnosis. In particular the following conditions, which may precede jaundice, should be taken into consideration, especially in patients at risk (see above: &#39;Conditions of occurrence&#39;):</p><p>- non-specific symptoms, usually of sudden onset, such as asthenia, malaise, anorexia, lethargy, oedema and drowsiness, which are sometimes associated with repeated vomiting and abdominal pain.</p><p><strong>- </strong>in patients with epilepsy, recurrence of seizures.</p><p>These are an indication for immediate withdrawal of the drug.</p><p>Patients (or their family for children) should be instructed to report immediately any such signs to a physician should they occur. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately.</p><p><u>Detection</u>:</p><p>Liver function should be measured before therapy and then periodically monitored during the first 6 months of therapy, especially in those who seem most at risk, and those with a prior history of liver disease.</p><p>Amongst usual investigations, tests which reflect protein synthesis, particularly prothrombin rate, are most relevant.</p><p>Confirmation of an abnormally low prothrombin rate, particularly in association with other biological abnormalities (significant decrease in fibrinogen and coagulation factors; increased bilirubin level and raised transaminases) requires cessation of Depakine therapy.</p><p>As a matter of precaution and in case they are taken concomitantly salicylates should also be discontinued since they employ the same metabolic pathway.</p><p>As with most anti-epileptic drugs, increased liver enzymes are common, particularly at the beginning of therapy; they are also transient.</p><p>More extensive biological investigations (including prothrombin rate) are recommended in these patients; a reduction in dosage may be considered when appropriate and tests should be repeated as necessary.</p><p><strong><em>Pancreatitis:</em></strong><strong> </strong></p><p>Pancreatitis, which may be severe and result in fatalities, has been very rarely reported. Patients experiencing nausea, vomiting or acute abdominal pain should have a prompt medical evaluation (including measurement of serum amylase).Young children are at particular risk; this risk decreases with increasing age. Severe seizures and severe neurological impairment with combination anti-convulsant therapy may be risk factors. Hepatic failure with pancreatitis increases the risk of fatal outcome. In case of pancreatitis, Depakine should be discontinued.</p><p><strong><em>Female children, women of childbearing potential and pregnant women:</em></strong><strong> </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Pregnancy Prevention Programme</u></strong><strong> </strong></p><p>Valproate has a high teratogenic potential and children exposed <em>in utero</em> to valproate have a high risk for congenital malformations and neurodevelopmental disorders (see section 4.6).</p><p>Depakine is contraindicated in the following situations:</p><p>&bull; In pregnancy unless there is no suitable alternative treatment (see sections 4.3 and 4.6).</p><p>&bull; In women of childbearing potential unless the conditions of the pregnancy prevention programme are fulfilled (see section 4.3 and 4.6).</p><p><u>Conditions of Pregnancy Prevention Programme:</u></p><p>The prescriber must ensure that:</p><p>&bull; Individual circumstances should be evaluated in each case. Involving the patient in the discussion to guarantee her engagement, discuss therapeutic options and ensure her understanding of the risks and the measures needed to minimise the risks.</p><p>&bull; The potential for pregnancy is assessed for all female patients.</p><p>&bull; The patient has understood and acknowledged the risks of congenital malformations and neurodevelopmental disorders including the magnitude of these risks for children exposed to valproate <em>in utero.</em></p><p>&bull; The patient understands the need to undergo pregnancy testing prior to initiation of treatment and during treatment, as needed.</p><p>&bull; The patient is counselled regarding contraception, and that the patient is capable of complying with the need to use effective contraception (for further details please refer to subsection contraception of this boxed warning), without interruption during the entire duration of treatment with valproate.</p><p>&bull; The patient understands the need for regular (at least annual) review of treatment by a specialist experienced in the management of epilepsy.</p><p>&bull; The patient understands the need to consult her physician as soon as she is planning pregnancy to ensure timely discussion and switching to alternative treatment options prior to conception and before contraception is discontinued.</p><p>&bull; The patient understands the need to urgently consult her physician in case of pregnancy.</p><p>&bull; The patient has received the Patient Guide.</p><p>&bull; The patient has acknowledged that she has understood the hazards and necessary precautions associated with valproate use (Annual Risk Acknowledgement Form).</p><p>These conditions also concern women who are not currently sexually active unless the prescriber considers that there are compelling reasons to indicate that there is no risk of pregnancy.</p><p><u>Female children</u></p><p>The prescriber must ensure that:</p><p>&bull; The parents/caregivers of female children understand the need to contact the specialist once the female child using valproate experiences menarche.</p><p>&bull; The parents/caregivers of female children who have experienced menarche are provided with comprehensive information about the risks of congenital malformations and neurodevelopmental disorders including the magnitude of these risks for children exposed to valproate <em>in utero.</em></p><p>In patients who have experienced menarche, the prescribing specialist must annually reassess the need for valproate therapy and consider alternative treatment options. If valproate is the only suitable treatment, the need for using effective contraception and all other conditions of the pregnancy prevention programme should be discussed. Every effort should be made by the specialist to switch female children to alternative treatment before they reach adulthood.</p><p><u>Pregnancy test</u></p><p>Pregnancy must be excluded before start of treatment with valproate. Treatment with valproate must not be initiated in women of childbearing potential without a negative pregnancy test (plasma pregnancy test) result, confirmed by a healthcare provider, to rule out unintended use in pregnancy.</p><p><u>Contraception</u></p><p>Women of childbearing potential who are prescribed valproate must use effective contraception without interruption during the entire duration of treatment with valproate. These patients must be provided with comprehensive information on pregnancy prevention and should be referred for contraceptive advice if they are not using effective contraception. At least one effective method of contraception (preferably a user independent form such as an intra-uterine device or implant) or two complementary forms of contraception including a barrier method should be used. Individual circumstances should be evaluated in each case when choosing the contraception method, involving the patient in the discussion to guarantee her engagement and compliance with the chosen measures. Even if she has amenorrhea she must follow all the advice on effective contraception.</p><p><u>Annual treatment reviews by a specialist</u></p><p>The specialist should review at least annually whether valproate is the most suitable treatment for the patient. The specialist should discuss the Annual Risk Acknowledgement Form at initiation and during each annual review, and ensure that the patient has understood its content.</p><p><u>Pregnancy planning</u></p><p>If a woman is planning to become pregnant, a specialist experienced in the management of epilepsy must reassess valproate therapy and consider alternative treatment options. Every effort should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued (see section 4.6). If switching is not possible, the woman should receive further counselling regarding the risks of valproate for the unborn child to support her informed decision-making regarding family planning.</p><p><u>In case of pregnancy</u></p><p>If a woman using valproate becomes pregnant, she must be immediately referred to a specialist to re-evaluate treatment with valproate and consider alternative treatment options. The patients with valproate-exposed pregnancy and their partners should be referred to a specialist experienced in prenatal medicine for evaluation and counselling regarding the exposed pregnancy (see section 4.6).</p><p><u>Pharmacists must ensure that:</u></p><p>&bull; The Patient Card is provided with every valproate dispensation and that patients understand its content.</p><p>&bull; Patients are advised not to stop valproate medication and to immediately contact a specialist in case of planned or suspected pregnancy.</p><p><u>Educational materials</u></p><p>In order to assist healthcare professionals and patients in avoiding exposure to valproate during pregnancy, the Marketing Authorisation Holder has provided educational materials to reinforce the warnings, provide guidance regarding use of valproate in women of childbearing potential and provide details of the Pregnancy Prevention Programme. A Patient Guide and Patient Card should be provided to all women of childbearing potential using valproate.</p><p>An Annual Risk Acknowledgement Form needs to be used at time of treatment initiation and during each annual review of valproate treatment by the specialist.</p><p>Valproate therapy should only be continued after a reassessment of the benefits and risks of the treatment with valproate for the patient by a specialist experienced in the management of epilepsy.</p></td></tr></tbody></table><p><strong><em>Aggravated convulsions: </em></strong></p><p>As with other anti-epileptic drugs, some patients may experience, instead of an improvement, a reversible worsening of convulsion frequency and severity (including status epilepticus), or the onset of new types of convulsions with valproate. In case of aggravated convulsions, the patients should be advised to consult their physician immediately (see section 4.8).</p><p><strong><em>Suicidal ideation and behaviour:</em></strong><strong> </strong></p><p>Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data does not exclude the possibility of an increased risk for sodium valproate.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p><strong><em>Carbapenem agents:</em></strong><strong> </strong></p><p>The concomitant use of valproate and carbapenem agents is not recommended.</p><p><strong><em>Patients with known or suspected mitochondrial disease: </em></strong></p><p>Valproate may trigger or worsen clinical signs of underlying mitochondrial diseases caused by mutations of mitochondrial DNA as well as the nuclear encoded POLG gene. In particular, valproate-induced acute liver failure and liver-related deaths have been reported at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations in the gene for the mitochondrial enzyme polymerase &gamma; (POLG), e.g. Alpers-Huttenlocher Syndrome.</p><p>POLG-related disorders should be suspected in patients with a family history or suggestive symptoms of a POLG-related disorder, including but not limited to unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus at presentation, developmental delays, psychomotor regression, axonal sensorimotor neuropathy, myopathy cerebellar ataxia, opthalmoplegia, or complicated migraine with occipital aura. POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders (see section 4.3).</p><p><strong>4.4.2 Precautions</strong></p><p><strong><em>Haematological:</em></strong><strong> </strong></p><p>Blood tests (blood cell count, including platelet count, bleeding time and coagulation tests) are recommended prior to initiation of therapy or before surgery, and in case of spontaneous bruising or bleeding (see section 4.8 Undesirable Effects).</p><p><strong><em>Renal insufficiency:</em></strong><strong> </strong></p><p>In patients with renal insufficiency, it may be necessary to decrease dosage. As monitoring of plasma concentrations may be misleading, dosage should be adjusted according to clinical monitoring (see sections 4.2 Posology and Method of Administration and 5.2. Pharmacokinetic Properties).</p><p><strong><em>Systemic lupus erythematosus:</em></strong><strong> </strong></p><p>Although immune disorders have only rarely been noted during the use of Depakine, the potential benefit of Depakine should be weighed against its potential risk in patients with systemic lupus erythematosus (see also section 4.8 Undesirable Effects).</p><p><strong><em>Hyperammonaemia:</em></strong><strong> </strong></p><p>When a urea cycle enzymatic deficiency is suspected, metabolic investigations should be performed prior to treatment because of the risk of hyperammonaemia with Depakine (see section 4.3).</p><p><strong><em>Weight gain:</em></strong><strong> </strong></p><p>Depakine very commonly causes weight gain, which may be marked and progressive. Patients should be warned of the risk of weight gain at the initiation of therapy and appropriate strategies should be adopted to minimise it (see section 4.8 Undesirable Effects).</p><p><strong><em>Diabetic patients:</em></strong></p><p>Depakine is eliminated mainly through the kidneys, partly in the form of ketone bodies; this may give false positives in the urine testing of possible diabetics.</p><p>Patients with an underlying carnitine palmitoyltransferase (CPT) type II deficiency should be warned of the greater risk of rhabdomyolysis when taking Depakine.</p><p><strong><em>Alcohol:</em></strong><strong> </strong></p><p>Alcohol intake is not recommended during treatment with valproate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5.1 Effects of Depakine on other drugs</strong></p><p>- <strong><em>Antipsychotics, MAO inhibitors, antidepressants and benzodiazepines</em></strong></p><p>Depakine may potentiate the effect of other psychotropics such as antipsychotics, MAO inhibitors, antidepressants and benzodiazepines; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.</p><p>In particular, a clinical study has suggested that adding olanzapine to valproate or lithium therapy may significantly increase the risk of certain adverse events associated with olanzapine e.g. neutropenia, tremor, dry mouth, increased appetite and weight gain, speech disorder and somnolence.</p><p>- <strong><em>Lithium</em></strong></p><p>Depakine has no effect on serum lithium levels.</p><p>- <strong><em>Olanzapine</em></strong></p><p>Valproic acid may decrease the olanzapine plasma concentration.</p><p>- <strong><em>Phenobarbital</em></strong></p><p>Depakine increases phenobarbital plasma concentrations (due to inhibition of hepatic catabolism) and sedation may occur, particularly in children. Therefore, clinical monitoring is recommended throughout the first 15 days of combined treatment with immediate reduction of phenobarbital doses if sedation occurs and determination of phenobarbital plasma levels when appropriate.</p><p>- <strong><em>Primidone</em></strong></p><p>Depakine increases primidone plasma levels with exacerbation of its adverse effects (such as sedation); these signs cease with long term treatment. Clinical monitoring is recommended especially at the beginning of combined therapy with dosage adjustment when appropriate.</p><p>- <strong><em>Phenytoin</em></strong></p><p>Depakine decreases phenytoin total plasma concentration. Moreover Depakine increases phenytoin free form with possible overdose symptoms (valproic acid displaces phenytoin from its plasma protein binding sites and reduces its hepatic catabolism). Therefore clinical monitoring is recommended; when phenytoin plasma levels are determined, the free form should be evaluated.</p><p>- <strong><em>Carbamazepine</em></strong></p><p>Clinical toxicity has been reported when Depakine was administered with carbamazepine as Depakine may potentiate toxic effects of carbamazepine. Clinical monitoring is recommended especially at the beginning of combined therapy with dosage adjustment when appropriate.</p><p>- <strong><em>Lamotrigine</em></strong></p><p>Depakine reduces the metabolism of lamotrigine and increases the lamotrigine mean half-life by nearly to fold. This interaction may lead to increased lamotrigine toxicity, in particular serious skin rashes. Therefore clinical monitoring is recommended and dosages should be adjusted (lamotrigine dosage decreased) when appropriate.</p><p>- <strong><em>Felbamate</em></strong></p><p>Valproic acid may decrease the felbamate mean clearance by up to 16%.</p><p>- <strong><em>Rufinamide</em></strong></p><p>Valproic acid may lead to an increase in plasma levels of rufinamide. This increase is dependent on concentration of valproic acid. Caution should be exercised, in particular in children, as this effect is larger in this population.</p><p>- <strong><em>Propofol</em></strong></p><p>Valproic acid may lead to an increased blood level of propofol. When co-administered with valproate, a reduction of the dose of propofol should be considered.</p><p>- <strong><em>Zidovudine</em></strong></p><p>Depakine may raise zidovudine plasma concentration leading to increased zidovudine toxicity.</p><p>- <strong><em>Nimodipine</em></strong></p><p>In patients concomitantly treated with sodium valproate and nimodipine the exposure to nimodipine can be increased by 50%. The nimodipine dose should therefore be decreased in case of hypotension.</p><p>- <strong><em>Vitamin K-dependent anticoagulants</em></strong></p><p>The anticoagulant effect of warfarin and other coumarin anticoagulants may be increased following displacement from plasma protein binding sites by valproic acid. The prothrombin time should be closely monitored.</p><p>- <strong><em>Temozolomide</em></strong></p><p>Co-administration of temozolomide and Depakine may cause a small decrease in the clearance of temozolomide that is not thought to be clinically relevant.</p><p><strong>4.5.2 Effects of other drugs on Depakine</strong></p><p>Anti-epileptics with enzyme inducing effect (including <strong><em>phenytoin, phenobarbital, carbamazepine</em></strong>) decrease valproic acid plasma concentrations. Dosages should be adjusted according to clinical response and blood levels in case of combined therapy.</p><p>Valproic acid metabolite levels may be increased in the case of concomitant use<strong> </strong>with <strong><em>phenytoin</em></strong> or <strong><em>phenobarbital</em></strong>. Therefore patients treated with those two drugs should be carefully monitored for signs and symptoms of hyperammonaemia.</p><p>On the other hand, combination of <strong><em>felbamate</em></strong> and Depakine decreases valproic acid clearance by 22% &ndash; 50% and consequently increase the valproic acid plasma concentrations. Depakine dosage should be monitored.</p><p><strong><em>Mefloquine</em></strong><strong> </strong>and <strong><em>chloroquine</em></strong> increase valproic acid metabolism and may lower the seizure threshold; therefore epileptic seizures may occur in cases of combined therapy. Accordingly, the dosage of Depakine may need adjustment.</p><p>In case of concomitant use of Depakine and <strong><em>highly protein bound agents (e.g. aspirin)</em></strong>, free valproic acid plasma levels may be increased.</p><p>Valproic acid plasma levels may be increased (as a result of reduced hepatic metabolism) in case of concomitant use with <strong><em>cimetidine</em></strong> or <strong><em>erythromycin</em></strong>.</p><p><strong><em>Carbapenem antibiotics</em></strong><strong> </strong>such as <strong><em>imipenem panipenem </em></strong>and <strong><em>meropenem</em></strong>: Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60% &ndash; 100% decrease in valproic acid levels within two days, sometimes associated with convulsions. Due to the rapid onset and the extent of the decrease, co-administration of carbapenem agents in patients stabilised on valproic acid should be avoided (section 4.4). If treatment with these antibiotics cannot be avoided, close monitoring of valproic acid blood levels should be performed.</p><p><strong><em>Protease inhibitors </em></strong>such as <strong><em>lopinavir </em></strong>and <strong><em>ritonavir</em></strong> decrease valproate plasma level when co-administered.</p><p><strong><em>Cholestyramine</em></strong><strong> </strong>may lead to a decrease in plasma level of valproate when co-administered.</p><p><strong><em>Rifampicin </em></strong>may decrease the valproic acid blood levels resulting in a lack of therapeutic effect. Therefore, valproate dosage adjustment may be necessary when it is co-administered with rifampicin.</p><p><strong>4.5.3 Other interactions</strong></p><p>Caution is advised when using Depakine in combination with newer anti-epileptics whose pharmacodynamics may not be well established.</p><p>Concomitant administration of valproate and <strong><em>topiramate</em></strong> or <strong><em>acetazolamide </em></strong>has been associated with encephalopathy and/or hyperammonaemia. In patients taking these two drugs, careful monitoring of signs and symptoms is advised in particularly at-risk patients such as those with pre-existing encephalopathy.</p><p>- <strong><em>Quetiapine</em></strong></p><p>Co-administration of Depakine and quetiapine may increase the risk of neutropenia/leucopenia.</p><p>Depakine usually has no enzyme-inducing effect; as a consequence, Depakine does not reduce efficacy of oestroprogestative agents in women receiving hormonal contraception, including the oral contraceptive pill.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&bull; Valproate is contraindicated as treatment for epilepsy during pregnancy unless there is no suitable alternative to treat epilepsy.</p><p>&bull; Valproate is contraindicated for use in women of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p><em>Pregnancy exposure risk related to valproate</em></p><p>Both valproate monotherapy and valproate polytherapy are associated with abnormal pregnancy outcomes. Available data suggest that anti-epileptic polytherapy including valproate is associated with a greater risk of congenital malformations than valproate monotherapy.</p><p><u>Teratogenicity and developmental effects</u></p><p><em>Congenital malformations </em></p><p>Data derived from a meta-analysis (including registries and cohort studies) has shown that 10.73% of children of epileptic women exposed to valproate monotherapy during pregnancy suffer from congenital malformations (95% CI: 8.16 &ndash; 13.29). This is a greater risk of major malformations than for the general population, for whom the risk is about 2 &ndash; 3%. The risk is dose dependent but a threshold dose below which no risk exists cannot be established.</p><p>Available data show an increased incidence of minor and major malformations. The most common types of malformations include neural tube defects, facial dysmorphism, cleft lip and palate, craniostenosis, cardiac, renal and urogenital defects, limb defects (including bilateral aplasia of the radius), and multiple anomalies involving various body systems.</p><p><em>Developmental disorders </em></p><p>Data have shown that exposure to valproate in utero can have adverse effects on mental and physical development of the exposed children. The risk seems to be dose-dependent but a threshold dose below which no risk exists, cannot be established based on available data. The exact gestational period of risk for these effects is uncertain and the possibility of a risk throughout the entire pregnancy cannot be excluded.</p><p>Studies in preschool children exposed in utero to valproate show that up to 30 &ndash; 40% experience delays in their early development such as talking and walking later, lower intellectual abilities, poor language skills (speaking and understanding) and memory problems.</p><p>Intelligence quotient (IQ) measured in school aged children (age 6) with a history of valproate exposure in utero was on average 7 &ndash; 10 points lower than those children exposed to other anti-epileptics. Although the role of confounding factors cannot be excluded, there is evidence in children exposed to valproate that the risk of intellectual impairment may be independent from maternal IQ.</p><p>There are limited data on the long term outcomes.</p><p>Available data show that children exposed to valproate in utero are at increased risk of autistic spectrum disorder (approximately three-fold) and childhood autism (approximately five-fold) compared with the general study population.</p><p>Limited data suggests that children exposed to valproate in utero may be more likely to develop symptoms of attention deficit/hyperactivity disorder (ADHD).</p><p><em>Female children and woman of childbearing potential (see above and section 4.4) </em></p><p><em>If a woman plans a pregnancy </em></p><p>If a woman is planning to become pregnant, a specialist experienced in the management of epilepsy must reassess valproate therapy and consider alternative treatment options. Every effort should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued (see section 4.4). If switching is not possible, the woman should receive further counselling regarding the risks of valproate for the unborn child to support her informed decision-making regarding family planning.</p><p><em>Pregnant women</em></p><p>Valproate as treatment for epilepsy is contraindicated in pregnancy unless there is no suitable alternative treatment (see sections 4.3 and 4.4). If a woman using valproate becomes pregnant, she must be immediately referred to a specialist to consider alternative treatment options.</p><p>During pregnancy, maternal tonic clonic seizures and status epilepticus with hypoxia may carry a particular risk of death for the mother and the unborn child. If in exceptional circumstances, despite the known risks of valproate in pregnancy and after careful consideration of alternative treatment, a pregnant woman must receive valproate for epilepsy, it is recommended to:</p><p>&bull; Use the lowest effective dose and divide the daily dose valproate into several small doses to be taken throughout the day.</p><p>&bull; The use of a prolonged release formulation may be preferable to other treatment formulations in order to avoid high peak plasma concentrations (see section 4.2).</p><p>All patients with valproate-exposed pregnancy and their partners should be referred to a specialist experienced in prenatal medicine for evaluation and counselling regarding the exposed pregnancy. Specialised prenatal monitoring should take place to detect the possible occurrence of neural tube defects or other malformations. Folate supplementation before the pregnancy may decrease the risk of neural tube defects which may occur in all pregnancies. However the available evidence does not suggest it prevents the birth defects or malformations due to valproate exposure.</p><p><u>Risk in the neonate </u></p><p>&bull; Cases of haemorrhagic syndrome have been reported very rarely in neonates whose mothers have taken valproate during pregnancy. This haemorrhagic syndrome is related to thrombocytopenia, hypofibrinogenemia and/or to a decrease in other coagulation factors. Afibrinogenemia has also been reported and may be fatal. However, this syndrome must be distinguished from the decrease of the vitamin-K factors induced by phenobarbital and enzymatic inducers. Therefore, platelet count, fibrinogen plasma level, coagulation tests and coagulation factors should be investigated in neonates.</p><p>&bull; Cases of hypoglycaemia have been reported in neonates whose mothers have taken valproate during the third trimester of their pregnancy.</p><p>&bull; Cases of hypothyroidism have been reported in neonates whose mothers have taken valproate during pregnancy.</p><p>&bull; Withdrawal syndrome (such as, in particular, agitation, irritability, hyper-excitability, jitteriness, hyperkinesia, tonicity disorders, tremor, convulsions and feeding disorders) may occur in neonates whose mothers have taken valproate during the last trimester of their pregnancy.</p><p><u>Breast-feeding </u></p><p>Valproate is excreted in human milk with a concentration ranging from 1% &ndash; 10% of maternal serum levels. Haematological disorders have been shown in breastfed newborns/infants of treated women (see section 4.8).</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Depakine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>Amenorrhoea, polycystic ovaries and increased testosterone levels have been reported in women using valproate (see section 4.8). Valproate administration may also impair fertility in men (see section 4.8). Case reports indicate that fertility dysfunctions are reversible after treatment discontinuation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use of Depakine may provide seizure control such that the patient may be eligible to hold a driving licence.</p><p>Patients should be warned of the risk of transient drowsiness, especially in cases of anti-convulsant polytherapy or association with benzodiazepines (see section 4.5 Interactions with Other Medicaments and Other Forms of Interaction).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following CIOMS frequency rating is used, when applicable: Very common (&ge; 1/10); common (&ge; 1/100 to &le; 1/10); uncommon (&ge; 1/1,000 to &le; 1/100); rare (&ge; 1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000); not known (cannot be estimated from the available data).</p><p><u>Congenital malformations and developmental disorders</u> (see section 4.4 and section 4.6).</p><p><u>Hepatobiliary disorders:</u></p><p><em>Common:</em> liver injury (see section 4.4.1 Warnings)</p><p>Severe liver damage, including hepatic failure sometimes resulting in death, has been reported (see also sections 4.2, 4.3 and 4.4.1). Increased liver enzymes are common, particularly early in treatment, and may be transient (see section 4.4.1).</p><p><u>Gastrointestinal disorders</u></p><p><em>Very common:</em> nausea</p><p><em>Common:</em> vomiting, gingival disorder (mainly gingival hyperplasia), stomatitis, gastralgia, diarrhoea</p><p>The above adverse events frequently occur at the start of treatment, but they usually disappear after a few days without discontinuing treatment. These problems can usually be overcome by taking Depakine with or after food.</p><p><em>Uncommon:</em> pancreatitis, sometimes lethal (see section 4.4 Special Warnings and Special Precautions for Use)</p><p><u>Nervous system disorders: </u></p><p><em>Very common:</em> tremor</p><p><em>Common:</em> extrapyramidal disorder, stupor*, somnolence, convulsion*, memory impairment, headache, nystagmus</p><p><em>Uncommon:</em> coma*, encephalopathy, lethargy* (see below), reversible parkinsonism, ataxia, paraesthesia, aggravated convulsions (see section 4.4)</p><p><em>Rare:</em> reversible dementia associated with reversible cerebral atrophy, cognitive disorder</p><p>Sedation has been reported occasionally, usually when in combination with other anti-convulsants. In monotherapy it occurred early in treatment on rare occasions and is usually transient.</p><p>*Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have very rarely been observed. These cases have often been associated with too high a starting dose or too rapid a dose escalation or concomitant use of other anti-convulsants, notably phenobarbital or topiramate. They have usually been reversible on withdrawal of treatment or reduction of dosage.</p><p>An increase in alertness may occur; this is generally beneficial but occasionally aggression, hyperactivity and behavioural deterioration have been reported.</p><p><u>Psychiatric disorders:</u></p><p><em>Common:</em> confusional state, hallucinations, aggression*, agitation*, disturbance in attention*</p><p><em>Rare:</em> abnormal behaviour*, psychomotor hyperactivity*, learning disorder*</p><p>*These ADRs are principally observed in the paediatric population.</p><p><u>Metabolism and nutrition disorders:</u></p><p><em>Common:</em> hyponatraemia, weight increased*</p><p>*Weight increase should be carefully monitored since it is a factor for polycystic ovary syndrome (see section 4.4).</p><p><em>Rare:</em> hyperammonaemia* (see section 4.4.2 Precautions), obesity</p><p>*Cases of isolated and moderate hyperammonaemia without change in liver function tests may occur, are usually transient and should not cause treatment discontinuation. However, they may present clinically as vomiting, ataxia, and increasing clouding of consciousness. Should these symptoms occur Depakine should be discontinued.</p><p>Hyperammonaemia associated with neurological symptoms has also been reported (see section 4.4.2 Precautions). In such cases further investigations should be considered.</p><p><u>Endocrine Disorders:</u></p><p><em>Uncommon:</em> Syndrome of Inappropriate Secretion of ADH (SIADH), hyperandrogenism (hirsutism, virilism, acne, male pattern alopecia, and/or androgen increase)</p><p><em>Rare:</em> hypothyroidism (see section 4.6 Fertility, pregnancy and lactation)</p><p><u>Blood and lymphatic system disorders:</u></p><p><em>Common:</em> anaemia, thrombocytopenia, (see section 4.4.2 Precautions)</p><p><em>Uncommon:</em> pancytopenia, leucopenia</p><p>The blood picture returned to normal when the drug was discontinued.</p><p><em>Rare:</em> bone marrow failure, including pure red cell aplasia, agranulocytosis, anaemia macrocytic, macrocytosis</p><p>Isolated findings of a reduction in blood fibrinogen and/or an increase in prothrombin time have been reported, usually without associated clinical signs and particularly with high doses (Depakine has an inhibitory effect on the second phase of platelet aggregation). Spontaneous bruising or bleeding is an indication for withdrawal of medication pending investigations (see also section 4.6 Fertility, pregnancy and lactation).</p><p><u>Skin and subcutaneous tissue disorders:</u></p><p><em>Common:</em> hypersensitivity, transient and/or dose related alopecia (hair loss), nail and nail bed disorders. Regrowth normally begins within six months, although the hair may become more curly than previously.</p><p><em>Uncommon:</em> angioedema, rash, hair disorder (such as abnormal hair texture, hair colour changes, abnormal hair growth)<em>Rare:</em> toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome</p><p><u>Reproductive system and breast disorders:</u></p><p><em>Common:</em> dysmenorrhea</p><p><em>Uncommon:</em> amenorrhea</p><p><em>Rare: </em>male infertility, polycystic ovaries</p><p>Very rarely gynaecomastia has occurred.</p><p><u>Vascular disorders: </u></p><p><em>Common:</em> haemorrhage (see section 4.4.2 Precautions and 4.6 Fertility, pregnancy and lactation)</p><p><em>Uncommon:</em> vasculitis</p><p><u>Ear and labyrinth disorders: </u></p><p><em>Common:</em> deafness, a cause and effect relationship has not been established.</p><p><u>Renal and urinary disorders: </u></p><p><em>Uncommon:</em> renal failure</p><p><em>Rare:</em> enuresis, tubulointerstitial nephritis, reversible Fanconi syndrome (a defect in proximal renal tubular function giving rise to glycosuria, amino aciduria, phosphaturia, and uricosuria) associated with Depakine therapy, but the mode of action is as yet unclear.</p><p><u>General disorders and administration site conditions: </u></p><p><em>Uncommon:</em> hypothermia, non-severe peripheral oedema</p><p><u>Musculoskeletal and connective tissue disorders:</u></p><p><em>Uncommon:</em> bone mineral density decreased, osteopenia, osteoporosis and fractures in patients on long-term therapy with Depakine. The mechanism by which Depakine affects bone metabolism has not been identified.</p><p><em>Rare:</em> systemic lupus erythematosus, rhabdomyolysis (see section 4.4.2 Precautions)</p><p><u>Respiratory, thoracic and mediastinal disorders:</u></p><p><em>Uncommon:</em> pleural effusion</p><p><u>Investigations:</u></p><p><em>Rare:</em> coagulation factors decreased (at least one), abnormal coagulation tests (such as prothrombin time prolonged, activated partial thromboplastin time prolonged, thrombin time prolonged, INR prolonged) (see sections 4.4 and 4.6)</p><p><u>Neoplasms benign, malignant and unspecified (including cysts and polyps):</u></p><p><em>Rare:</em> myelodysplastic syndrome</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sanofi- Pharmacovigilance:<strong> </strong>KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of accidental and deliberate Depakine overdose have been reported. At plasma concentrations of up to 5 &ndash; 6 times the maximum therapeutic levels, there are unlikely to be any symptoms other than nausea, vomiting and dizziness.</p><p>Signs of acute massive overdose, i.e. plasma concentration 10 &ndash; 20 times maximum therapeutic levels, usually include CNS depression or coma with muscular hypotonia, hyporeflexia, miosis, impaired respiratory function, metabolic acidosis, hypotension and circulatory collapse/shock. A favourable outcome is usual, however some deaths have occurred following massive overdose.</p><p>Symptoms may however be variable and seizures have been reported in the presence of very high plasma levels (see also section 5.2 Pharmacokinetic Properties). Cases of intracranial hypertension related to cerebral oedema have been reported.</p><p>The presence of sodium content in the Depakine formulations may lead to hypernatraemia when taken in overdose.</p><p>Hospital management of overdose should be symptomatic, including cardio-respiratory monitoring. Gastric lavage may be useful up to 10 &ndash; 12 hours following ingestion.</p><p>Haemodialysis and haemoperfusion have been used successfully.</p><p>Naloxone has been successfully used in a few isolated cases, sometimes in association with activated charcoal given orally.</p><p>In case of massive overdose, haemodialysis and haemoperfusion have been used successfully.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium valproate and valproic acid are anti-convulsants.</p><p>The most likely mode of action for Depakine is potentiation of the inhibitory action of gamma amino butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA.</p><p>In certain <em>in-vitro </em>studies it was reported that Depakine could stimulate HIV replication but studies on peripheral blood mononuclear cells from HIV-infected subjects show that Depakine does not have a mitogen-like effect on inducing HIV replication. Indeed the effect of Depakine on HIV replication <em>ex-vivo </em>is highly variable, modest in quantity, appears to be unrelated to the dose and has not been documented in man.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The half-life of Depakine is usually reported to be within the range of 8 &ndash; 20 hours. It is usually shorter in children.</p><p>In patients with severe renal insufficiency it may be necessary to alter dosage in accordance with free plasma valproic acid levels.</p><p>The reported effective therapeutic range for plasma valproic acid levels is 40 &ndash; 100 mg/litre (278 &ndash; 694 micromol/litre). This reported range may depend on time of sampling and presence of co-medication. The percentage of free (unbound) drug is usually between 6% and 15% of total plasma levels. An increased incidence of adverse effects may occur with plasma levels above the effective therapeutic range.</p><p>The pharmacological (or therapeutic) effects of Depakine Chrono may not be clearly correlated with the total or free (unbound) plasma valproic acid levels.</p><p>Depakine Chrono formulations are prolonged release formulations which demonstrate in pharmacokinetic studies less fluctuation in plasma concentration compared with other established conventional and modified release Depakine formulations.</p><p>In cases where measurement of plasma levels is considered necessary, the pharmacokinetics of Depakine Chrono make the measurement of plasma levels less dependent upon time of sampling.</p><p>The Depakine Chrono formulations are bioequivalent to Depakine Liquid and enteric coated (EC) formulations with respect to the mean areas under the plasma concentration time curves. Steady-state pharmacokinetic data indicate that the peak concentration (C<sub>max</sub>) and trough concentration (C<sub>min</sub>) of Depakine Chrono lie within the effective therapeutic range of plasma levels found in pharmacokinetic studies with Depakine EC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylcellulose 20 mPa.s, hypromellose 300 mPa.s, anhydrous colloidal silica, hydrated colloidal silica, sodium saccharin, hypromellose 6 mPa.s, macrogol 6000, polyacrylate dispersion 30% (EUDRAGIT&reg; E30 D), talc, titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30&deg;C and protected from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(Aluminum/PVC/Aluminum) blisters of 30, 40, 60 or 100 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sanofi-aventis France 82 avenue Raspail 94250 Gentilly – France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>